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ABSTRACT 
 Integrins are major adhesion receptors for the extracellular matrix (ECM). This 
thesis focuses on the motifs and interactions within integrin cytoplasmic tails during 
integrin-mediated cell adhesion and spreading. The present study investigated the 
significance of the skelemin-αIIbβ3 interaction using Chinese Hamster Ovary (CHO) 
cells expressing wild-type or mutant αIIbβ3 receptors defective in skelemin binding. 
Most mutant cells displayed unimpaired adhesive capacity and spreading on 
immobilized fibrinogen at the early stages of cell spreading. In addition, they formed 
normal focal adhesions and stress fibers with no indication of impaired cell spreading. 
K716A, and H722A mutant cells exhibited the greatest cell spreading, which was 
associated with enhanced p-Src activation. The K716 residue appeared to be the most 
important for skelemin binding in previous in vitro studies. Here, the protrusions of 
the leading edge of K716A cells showed strong colocalization of talin with αIIbβ3 
which was associated with a loss in skelemin binding. These data suggest that the 
binding of skelemin to αIIbβ3 is not essential for normal cell spreading, but may act to 
exert contractile forces on cell spreading and coordinate the binding of talin to the 
membrane proximal region of integrin tails. The functional mode of peptides 
corresponding to the central motifs of the αIIb and αV tail, KRNRPPLEED (αIIb peptide) 
and KRVRPPQEEQ (αV peptide) was also investigated. Both peptides inhibited 
Mn2+-activated αIIbβ3 binding to soluble fibrinogen as well as the binding of 
αIIbβ3-expressing CHO cells to immobilized fibrinogen. Breast cancer progression has 
been linked to tumor cell interaction with ECM. Our αIIb and αV peptides also 
inhibited adhesion of two breast cancer cell lines (MDA-MB-435 and MCF7) to αV 
integrin ECM ligand vitronectin. Replacement of RPP with AAA significantly 
attenuated the inhibitory activity of the αIIb peptide. β-tubulin was identified as a 
potential αIIb peptide-binding partner, suggesting that microtubule cytoskeleton may 
participate in the regulation of integrin functions. These results provide insights into 
the mechanisms by which the central motifs of αIIb and αV tail regulate integrin 
activation and integrin-mediated cell adhesion. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Integrin functions 
Integrins are type I transmembrane proteins consisting of noncovalently linked α 
and β subunits. In mammals, 18 α subunits pair with 8 β subunits to form a large 
integrin family with at least 24 distinct integrin heterodimers (1) (Figure 1.1).  
 
 
Figure 1.1：The integrin family members. In vertebrates, the integrin family 
contains 24 heterodimers. They are divided into several subfamilies based on 
evolutionary relationships (coloring of α subunits), ligand specificity and 
leukocyte-specific expression in the case of β2 and β7 integrins. Adapted from 
reference (1). 
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Integrins are essential adhesion receptors that mediate cell-cell and cell-matrix 
interactions. Their primary function is to mediate cell adhesion, which provides a 
physical support for a cell and various tissue types. Each integrin family member can 
bind with multiple ECM proteins, such as bone matrix proteins, vitronectin, collagens, 
fibronectins, fibrinogen, laminins, thrombospondins, and von Willebrand factor. 
Integrins also bind with particular motifs or ligands. The preference of integrin 
binding is determined by the affinity, availability and conformation of ligands in the 
microenvironment (2). Cells expressing particular integrins can adhere or migrate 
toward a specific region where integrin ligands are available. Integrin attachment of 
cells to the ECM is important for the developmental processes (3). Genetic deletion 
studies with Drosophila melanogaster which have lower integrin redundancy 
suggested that disruption of αPS or βPS [Drosophila position-specific (PS) genes 
encode α or β integrin ortholog] resulted in embryonic lethal or defective tissue 
morphogenesis, such as muscle detachment, dorsal closure defects, delayed gut 
migration, and blisters in the wing (3).  
Integrin-mediated cell-cell adhesion is facilitated by the β2 family. β2 integrins are 
leukocyte-specific receptors and bind cellular receptor ligands such as vascular cell 
adhesion molecule-1 (VCAM-1) and/or intercellular cell adhesion molecule (ICAM) 
on endothelial cells (1, 4). β2 integrins are important for many adhesion-dependent 
processes, including chemotaxis, phagocytosis and homotypic aggregation. The lack 
of expression of β2 integrins or the expression of dysfunctional β2 integrins lead to 
leukocyte adhesion deficiency type I (LAD I) disease, a life-threatening condition 
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associated with recurrent microbial infections with associated neutrophilia (5). 
Not only can integrins mediate physical attachment of cells to their environment, 
but they can also be a primary component of sensory machinery for cells (6). By 
binding with their ligands, integrins recognize and sense environmental cues, 
including chemical or physical stimuli, and transmit these signals into cells. Diverse 
signalling pathways can be initiated and transmitted by integrin, which influence 
varieties of cell behaviours, such as cell adhesion, migration, proliferation, 
differentiation, and apoptosis. These basic biological events determine processes of 
embryonic development, tissue repair, homeostasis, and immune responses. Abnormal 
integrin function is linked to the progression of some diseases, such as thrombosis, 
autoimmune disease, and tumour metastasis. 
Our lab is particularly interested in integrin αIIbβ3, expressed on platelets, 
megakaryocytes, basophils, mast cells and some tumour cells (7). αIIbβ3 is the most 
abundant integin expressed on platelets and responsible for platelet aggregation and 
normal homeostasis. When αIIbβ3 is activated, it binds to multivalent fibrinogen and 
von Willebrand factors in plasma, which then bridge to other αIIbβ3 molecules on 
adjacent platelets leading to platelet-platelet interaction. Genetic defects in integrin 
αIIb or β3 subunit results in Glanzmann thrombasthenia, a bleeding disorder (8). 
 
1.2 Integrin activation 
Integrins are normally expressed on cells in an inactive state, and are unable to 
productively bind to their ligands. This is particularly important for immune cells and 
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platelets circulating in the bloodstream, as integrins must be in a quiescent state under 
physiological conditions. Stimuli such as cytokines and coagulation factors can 
quickly cause extracellular changes of integrins, switching integrins from a low ligand 
binding affinity state to a high affinity state (a process known as inside-out signalling). 
αIIbβ3 on platelets represents a typical model to investigate integrin activation. αIIbβ3 
in the low-affinity state does not interact with soluble fibrinogen under physiological 
conditions. After vascular injury, stimulation by a number of agonists (such as 
thrombin, ADP, epinephrine) on platelets changes the αIIbβ3 conformation and 
increases its affinity to fibrinogen. How these agonists initiate integrin activation 
(inside-out signalling pathway) is not completely clear, but a recent study suggested 
that platelet agonists can bind to specific G-protein-coupled receptors (GPCRs) in 
platelets, and the heterotrimeric G-protein may play a key role in translating the 
signal from GPCRs to integrin αIIbβ3 (9). Binding of fibrinogen to αIIbβ3 on platelets 
results in platelet aggregation. This quick and precisely controlled process is critical in 
order to prevent blood loss at the site of a wound, while maintaining normal blood 
flow. Abnormal αIIbβ3 activation leads to potentially life-threatening thrombosis and is 
involved in cardiovascular diseases. 
Another example of the control of integrin activation is integrin αVβ3, which is 
widely expressed in diverse cell types. αVβ3 is used as a marker of angiogenic 
vascular tissue as quiescent endothelial cells expressed low levels of αVβ3 but 
endothelial cells in angiogenic vessels have increased αVβ3 expression (10). 
Activation of αVβ3 can be induced by agonists, such as ADP, phorbol myristate 
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acetate (PMA) and Mn2+. PMA is also a potent activator of protein kinase C (PKC) 
(11). Previous work found that the PKC pathway is important for the inside-out 
signalling events that activate αVβ3 (11, 12). In addition, the neutral protease calpain, 
a secondary signalling molecule in cells, is also required for the modulation of αVβ3 
activation (11). Calpain cleaves a variety of substrates of multiple intracellular 
signalling pathways, including PKC (13). Moreover, αVβ3 has been implicated in 
tumour invasion and metastasis of several tumour types, such as glioma, breast 
cancer, and melanoma (14, 15). In breast cancer, the expression of αVβ3 on tumour 
cells, particularly in its high affinity state, promotes tumour progression and 
metastasis. Over-expression of the constitutively active mutant αVβ3D723R, but not 
wild-type αVβ3, in MDA-MB 435 cells resulted in a significant increase in metastatic 
activity in mouse models (16, 17). The drastic increase in metastatic activity of 
active αVβ3 has been attributed to its capability of supporting tumour cell arrest 
during blood flow through interaction with platelets, up-regulation of the mature 
form of metalloproteinase-9 (MMP-9) which maximizes tumour cell mobility, and 
efficient metastasis growth in metastatic tissue through continuous up-regulation of 
vascular endothelial growth factor (VEGF) (16, 18, 19).  
 
1.3 Integrin structure and the conformational change during integrin activation 
As a typical integrin, αIIbβ3 is a heterodimer composed of αIIb and β3, which are 
held together by numerous non-covalent protein-protein and protein-metal ion 
contacts. Each subunit has a large extracellular domain, a single-pass transmembrane 
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domain, and a short cytoplasmic tail. 
 
1.3.1 Extracellular domain 
The extracellular domain of integrin is a ligand binding region. The first X-ray 
crystal structure of the full-length extracellular domain of integrin was obtained from 
αvβ3 and its complex with the RGD peptide ligand (20, 21). The structure of αvβ3 
revealed the inter-subunit interface, ligand binding sites, some previously unpredicted 
modules, and novel calcium-binding sites. Ligand binding sites form a globular 
headpiece which is followed in each subunit by two long legs. The two subunit 
interface also lies within the head between the seven-bladed β–propeller in αv subunits 
and the βA-domain in β3 subunits (Figure 1.2). The β-propeller domain of the α 
subunit contains Ca2+-binding motifs that are important for formation of the 
inter-subunit interface. In the absence of a ligand, the structure folds into an extremely 
bent conformation and ligand binding induces an extended conformation as shown in 
Figure 1.2. Electron microscopy studies of αvβ3 reconstituted in lipid bilayers showed 
an extended conformation, especially when integrin was activated by Mn2+ and 
small-molecule ligands (22, 23). Therefore, there is a general acceptance that a bent 
structure represents an inactive state and that the extended structure exposes ligand 
binding sites and defines the active state.  
The crystal structures of αIIbβ3 with or without a bound ligand have also been 
resolved (24, 25). The αIIbβ3 structure is very similar to that of αvβ3 as shown in Figure  
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Figure 1.2: Ribbon schematic of crystallized αvβ3 in a bent (left) and extended 
conformation (right). αv is shown in blue and β3 in red. Its 12 known and novel 
domains assemble into a globular “head” and two “tails’’. Adapted from reference 
(21). 
 
1.2. However, an intermediate form of αIIbβ3 between the bent and extended form was 
reported in a cryo-electron microscopy (cryo-electron microscopy: imaging specimens 
in a transmission electron microscope under cryogenic conditions) study (26). The 
bent conformation of αIIbβ3 incorporated into liposomes was also observed in the 
presence of Mn2+ (27). Quantitative analysis of electron microscopic images of 
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lipid-embedded αIIbβ3 revealed that activation of integrin shifted the conformational 
equilibrium in favour of the extended form that leads to an increase in ligand binding 
affinity (28). 
Three metal binding sites in the βA domain of the β3 subunit support the ligand 
binding site (24). They are occupied by the divalent cations Ca2+ and Mg2+. A metal 
ion dependent adhesion site (MIDAS) in the βA-domain binds with Mg2+ and 
participates in ligand binding. MIDAS is flanked by two Ca2+ binding sites, named 
the adjacent metal ion dependent adhesion site (ADMIDAS) and the synergistic metal 
ion binding site (SyMBS) (24). ADMIDAS binds an inhibitory Ca2+ ion and 
replacement of Mn2+ at this site results in a structural change that produces an active 
integrin (29). 
 
1.3.2 Transmembrane domain 
The transmembrane domains (TMDs) of integrins are single membrane-spanning 
structures, comprised of about 20 amino acid residues, and are highly conserved 
across integrins. The TMD of integrin αIIbβ3 is rich in hydrophobic sequences and 
closely resembles that of many of the other 18 α and 8 β human subunits. Its 
C-termini are located close to lysine residues K989 in αIIb and K716 in β3, which 
begin the cytoplasmic regions. The TMD domain is critical for integrin activation and 
for transmitting signals across the plasma membrane. Studies of nuclear magnetic 
resonance (NMR) structure (26, 30, 31), disulfide bond scanning (32), and Leu 
substitution (33) found that there is an α-β heterodimeric TMD interaction in integrin 
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in its resting state. Dissociation of the α-β interaction at the TMD triggers receptor 
activation and signalling (33-35). 
NMR is a useful tool to study a weak and dynamic complex. By using NMR, 
most of the integrin TMD and cytoplasmic tail structural data were obtained in a 
variety of membrane mimetic solvents. NMR structures of the αIIbβ3 TMD show that 
the αIIb TMD adopts a short and straight helix structure, whereas the β3 TMD forms a 
long and tilted helix, which extends to the intracellular side and forms a continuous 
helix with the membrane-proximal region of β3 cytoplasmic tails (32, 36). At the 
N-terminus of the β3 TMD, Gly residues at 708, 976 and 972 allow close interhelical 
packing, which explains the observation that mutational substitution of either Gly 
residue with a bulky amino acid results in constitutively active integrin (33). This 
helical TMD packing is referred to as the outer membrane clasp (OMC) that stabilizes 
the low-affinity state of the integrin (31).  
 
1.3.3 Cytoplasmic tails: structures and interactions 
Integrin cytoplasmic domains are generally short, but vital in regulating integrin 
ligand-binding competency and signalling functions. The cytoplasmic tails are highly 
similar between αIIb and other integrin α-subunits, which are composed of a highly 
conserved N-terminus followed by a variable C-terminus (Figure 1.3). 
Early mutational studies show that deletion of almost the entire αIIb-cytoplasmic 
tail (G991–E1008) or deletion of α or β membrane-proximal regions constitutively 
activates αIIbβ3 (37, 38). Therefore, the membrane-proximal regions of αIIbβ3 tails were 
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Figure 1.3: Sequence alignment of various human integrin α-cytoplasmic 
domains. The sequence identity and similarity are highlighted in red and purple. 
Adapted from reference (4). 
 
 
suggested to negatively regulate integrin activation (38). The opposing charged 
Arg995 in αIIb and Asp723 in β3 were proposed to form a salt bridge (39). Charge 
reversal of either one of these residues (R995D or D723R) or substitution of either 
one with non-charged residues (for example, R995A) resulted in the expression of a 
constitutively active αIIbβ3. However, when both charges were reversed, the integrin 
stayed inactive (39). These studies indicate that the electronic interaction between 
membrane-proximal regions of αIIb or β3 maintains integrins in an inactive state, while 
breaking this interaction makes the integrin active (39). The interaction between αIIb 
and β3 cytoplasmic peptide can be detected by surface plasmon resonance (SPR). 
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Their heterodimerization occurred in a 1:1 stoichiometry with a weak affinity in the 
micromolar range, which was impaired by the R995A substitution or deletion of 
KVGFFKR in αIIb (40). 
The structures of αIIbβ3 cytoplasmic tails have been characterized under 
heterodimeric conditions (41-44). Most structural studies of αIIbβ3 identified 
electrostatic and hydrophobic interactions in the membrane proximal regions, which 
support the previous mutational studies. The interaction occurred between the 
conserved 990GFFKR995 in αIIb subunits and the conserved 722HDRKE726 in β3 tails. 
The current view is that both the interactions through the membrane-proximal regions 
and packing of TMDs are required to keep the resting integrin receptor in an inactive 
state and disrupting either interaction activates integrins (35, 45). Evidence for this 
view comes from the mutational study showing that the individual effects on integrin 
activation produced by mutations in the TMD or tail interface were weak, whereas the 
combination of the two mutations had a strong synergistic effect (36).    
The membrane distal region of the αIIb cytoplasmic tail has a significant structural 
feature, described as a turn formed at RPP999. The NMR structure of a synthetic 
peptide encompassing the αIIb cytoplasmic tail reveals a “closed” conformation 
(Figure 1.4A) (4). The highly conserved N-terminal membrane-proximal region forms 
an α-helix followed by a turn at PP which allows the acidic C-terminal loop to fold 
back and interact with the positively charged N-terminal helix. Replacing the double 
prolines with alanines (P998A/P999A) resulted in misfolding of αIIb (Figure 1.4B). 
Although the N-terminal α-helix is retained in the mutant peptide, the double mutation 
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disrupts the turn, thereby preventing interactions between the N-terminal helix and 
C-terminal region and resulting in an “open” conformation. The structure of the 
mutant is apparently less rigid, with a significantly reduced number of Nuclear 
Overhauser Effect (NOE) constraints in its NMR signals as a result of disruption of 
N- and C-terminal contacts. Furthermore, mutation of αIIbβ3 (P998A/P999A) 
expressed in CHO cells rendered αIIbβ3 constitutively active to bind extracellular 
ligands, resulting in fibrinogen-dependent cell-cell aggregation (46). 
 
 
 
Figure 1.4: Structural highlights of the cytoplasmic domain of αIIb. (A) Backbone 
of wild type αIIb showing the residues participating in the loop structure formation 
between the N-terminal helix and C-terminal region. The interactions between the N 
and C termini are primarily through an electrostatic network between the side chains 
of K994, R997, E1001, D1003, D1004, and E1005. (B) Backbone overlay of wild- 
type αIIb (purple) and mutant αIIb (yellow) showing the structural difference. Adapted 
from reference (4). 
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One possible reason for the activation of the mutated αIIbβ3 (P998A/P999A) is 
because the downstream activators can bind to the integrin tails when they are “open” 
(Figure 1.4) (4). Multiple proteins have been identified that bind to αIIb tails. For 
example, the αIIb cytoplasmic tail interacts with the chloride channel ICln, the 
calcium- and integrin-binding protein (CIB), and the catalytic subunit of protein 
phosphatase 1 (47-50). The binding of these cytoplasmic proteins may serve to 
regulate integrin activation and function. However, almost all of the proteins were 
reported to bind to the membrane proximal region of αIIb tails. Therefore, searching 
for proteins that interact with the central turn motif of αIIb tails may provide useful 
insights for understanding the significance of the turn structural feature which still 
remains uncertain.  
Compared with αIIb tails, the structure and function of β3 integrin tails have been 
more extensively studied. There are two well-defined motifs within β integrin tails: 
the NPxY747 motif (x stands for any amino acid and is a leucine in the β3 tail) and the 
NxxY759 motif (xx is isoleucine and threonine in the β3 tail). These motifs represent 
recognition sequences for phosphotyrosine-binding (PTB) domains (51). NPxY747 
serves as the binding site for talin, a well-established integrin activator. Talin binding 
has previously been assumed to be the final and common step of integrin activation 
(52, 53). The PTB domain within the head domain of talin binds to integrin β3 tails 
with much higher affinity (Kd～100nM). Y747 of NPLY747 within β3 tails is necessary 
for this interaction (54, 55). An NMR study showed that the talin-binding site on the 
β3 tail extended to the membrane proximal region, completely overlapping the region 
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of β3 interaction with αIIb. Adding a talin head destroyed the NMR signals of a αIIb-β3 
tail interface (43). Reconstitution of physiological integrin activation with nanodiscs 
and a single lipid-embedded integrin showed that talin binding alone was sufficient to 
activate integrin αIIbβ3 (28). These studies are consistent with the model that the 
membrane-proximal regions form the inner membrane clasp (IMC) that maintains the 
low-affinity state, and breaking this clasp induces integrin activation (31).. 
However, it is interesting that although many PTB-domain-containing proteins 
bind integrins, only talin exhibits the capacity to activate integrins. A further study 
found that a second interaction happens between talin and the membrane proximal 
helix of β3 tails, which causes α and β tail separation and in turn the extended and 
active conformation of the integrin extracellular domain (56). Several integrin 
activation inhibitors with PTB domains have been identified. These inhibitors, such as 
docking protein 1 (Dok1) and filamin, can bind to the β3 NPLY747 motif through its 
PTB domain but do not activate integrin, and thereby can function as competitive 
inhibitors of talin binding (51, 57). 
Recently, another protein, kindlin, has been identified as a direct integrin activator. 
Platelets lacking kindlin-3, which is specific to hematopoietic cells, were unable to 
activate integrins despite normal talin expression (58). Kindlin-1 and kindlin-2 can 
function as co-activators of talin and enhance the ability of overexpressed talin head 
domain to activate integrin αIIbβ3 in endothelial cells and CHO cells (59, 60). Their 
binding to β3 tails requires the β3 C-terminal region (NITY759) (59, 60). 
1.3.4 Integrin clustering  
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In addition to conformational changes of individual integrins, integrin activation 
promotes the lateral assembly of integrins (integrin clustering) within the plane of the 
plasma membrane. Integrin conformational changes and clustering are 
complementary for a cell to bind strongly to the ECM and for integrin signalling (61). 
Ligand affinity of individual integrins is increased by integrin activation, but for a cell 
to bind strongly to the ECM, it is not enough. Integrin clustering increases the avidity 
of binding so that the sum of hundreds or thousands of weak interactions constitute a 
tightly bound adhesive unit (3). In addition, integrin clustering is important for 
integrin outside-in signalling, increasing the local concentration of integrin-associated 
signalling molecules and triggering the activation of Src (a non-receptor tyrosine 
kinase encoded by the proto-oncogene of src which is highly similar to the v-src gene 
of Rous sarcoma virus) and FAK (focal adhesion kinase), as discussed in section 
1.5.3.2 of this chapter. 
αIIbβ3 clustering is promoted by extracellular and intracellular factors, including 
the binding of multivalent ligands, ligand self-association, relief from cytoskeletal 
constraints, and homomeric interactions of the transmembrane domains (62-65). 
Optimum oligomerization requires the participation of the integrin's transmembrane 
and cytoplasmic regions (66). However, whether the activated integrins can cluster 
spontaneously remains controversial. Protein fragments encompassing the 
transmembrane helix plus cytoplasmic tails of the α and β subunits of αIIbβ3 were able 
to form homodimers or homooligomers in phospholipid micelles (67, 68). It is 
possible that integrin TMDs interact heteromerically in the inactive state, but when 
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integrins are activated, the transmembrane domains separate and homooligomerize, 
which drives lateral clustering (62). However, cysteine scanning mutagenesis of 
integrin αIIbβ3 transmembrane domains did not reveal a specific interaction of these 
domains after integrin activation in living cells (69). Electron microscopic images of 
purified and activated αIIbβ3 integrins that were reconstituted into lipid bilayers did not 
show spontaneous clustering, but integrins clustered after fibrinogen binding (22). In 
a study using β-gal complementation and bioluminescence resonance energy transfer 
(BRET) assays to detect integrin clustering, direct activation of αIIbβ3 by MnCl2 or an 
activating antibody did not cause clustering in the absence of fibrinogen (64).  
 
1.4 Integrin outside-in signalling 
Once integrins are active and clustering, they can transmit information into cells, 
a process known as outside-in signalling. These intracellular changes can be divided 
into three temporal stages: immediate, short-term and long-term (3). Immediate 
intracellular changes include rapid phosphorylation events, particularly tyrosine 
phosphorylation of specific substrates, and an up-regulation of lipid second 
messengers such as phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) and 
phosphatidylinositol-3,4,5-triphosphate (PtdIns-3,4,5-P3). Short-term changes consist 
of cytoskeletal rearrangements, which are required for cell spreading, migration and 
polarity establishment. This step usually occurs within one hour of cell adhesion, and 
involves dynamic connections of integrins to the cell cytoskeleton, and activation of 
kinases and signal transduction pathways to regulate cytoskeletal rearrangements. 
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Long-term attachment to the ECM ultimately results in changes in signalling 
pathways and gene expression that influence the survival, growth, and differentiation 
of cells. Figure 1.5 shows the major signalling pathways and key players located 
downstream of integrin activation. 
 
 
 
Figure 1.5: Integrin outside-in signalling. Major signalling pathways and key 
players downstream of integrin activation are illustrated. Integrin regulates 
downstream signalling pathways in cooperation with growth factor receptors to 
influence cell proliferation, differentiation, cell shape and migration. 
Integrin-associated proteins linking integrins and these signal transduction pathways 
are shown within the pink-purple pentagon beneath the clustered integrins. Integrins 
activate ERK and JNK to regulate cell proliferation. Integrins regulate Rho GTPase 
activity through the Src/FAK complex, resulting in cytoskeletal organization and 
regulation of cell motility. Integrins also activate PI3K and regulate cell survival 
through Akt. Adapted from reference (1). 
The inside-out and outside-in signalling pathways constitute the bidirectional 
signalling across integrin receptors. Cytoplasmic tails of integrins serve as receivers 
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and transmitters of the bidirectional signal. Integrin cytoplasmic tails possess no 
enzymatic or kinase activity. One of the primary mechanisms of signal transduction is 
via recruiting cytoplasmic binding proteins following integrin activation and 
clustering. An overwhelming collection of cytoplasmic molecules that directly or 
indirectly interact with αIIbβ3 has been identified (70, 71). 
 
1.5 Integrin mediated cell adhesion and spreading 
1.5.1 Integrin adhesome 
Integrins mediate cell-matrix adhesion by linking the ECM to the actin 
cytoskeleton (1). First, ligand-bound integrins cluster together and engage other 
proteins to organize into small and transient cell-ECM contacts called nascent 
adhesions (72, 73). As cells spread and migrate, nascent adhesions either disassemble 
or progress to larger dot-like adhesions called focal complexes, which locate slightly 
back from the leading edge and persist for several minutes (74). In more fully 
spreading cells, focal complexes can mature into larger and elongated focal adhesions. 
Focal adhesions reside at the ends of actin stress fibers (bundles of actin filaments) 
(74). Focal adhesions and stress fibers are cellular structures that are important for 
exerting contractile forces during cell migration. 
Adhesion sites (nascent adhesions, focal complexes and focal adhesions) are large 
multiprotein complexes consisting of at least 180 signalling, structural, and adaptor 
molecules (75). These molecules and their interactions (at least 742) form a complex 
network termed the ‘integrin adhesome’ (75). In general, the integrin adhesome is 
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divided into structural and regulatory/signalling sub-networks (75, 76). The structural 
sub-network serves as a mechanical linkage between the ECM and cell cytoskeleton 
and generates traction force required for cell spreading and migration (1). Integrins 
anchor the intracellular cytoskeleton to the ECM by recruiting cytoskeletal proteins, 
such as talin, filament, α-actinin and tensin (76). These proteins can bind to F-actin and 
therefore couple integrins to the cytoskeleton directly (70). The regulatory/signalling 
sub-network includes multiple biochemical signalling hubs for many cellular 
processes, including actin polymerization and actomyosin contraction, cell 
proliferation and survival, and gene expression (77, 78). Integrins recruit and activate 
various catalytic proteins, such as FAK, integrin linked kinase (ILK), Src family 
kinase (SFK) and protein phosphatase 2A (PP2A). They facilitate the propagation of 
signal-transduction pathways from adhesion sites, and translate environmental cues 
into biochemical signals within cells (70). 
 
1.5.2 Cell spreading: integrin-mediated control of cell protrusion and contraction 
Cell spreading on the ECM requires two fundamental cellular processes, actin 
polymerization and actin-myosin contraction, the balance of which are tightly 
controlled and organized by integrin outside-in signalling (79, 80). After spherical 
cells in suspension adhere to the ECM, they quickly spread to a more flattened shape. 
They form protrusions at the cell leading edge, broad lamellipodia and spike-like 
filopodia. Formation of cell membrane protrusions is driven by actin polymerization 
(81). Actin polymerization is catalyzed by the ARP2/3 complex, which makes a 
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branched actin filament network through its actin nucleation function (82). After 
spreading, the cells form specialized structures such as stress fibers and focal 
adhesions. Contraction of actin stress fibers is mediated by myosin. During 
contraction, actin filaments do not shorten, but myosin mediates actin filaments to 
slide past each other (83). 
The balance between actin-mediated protrusions and myosin-mediated 
contractions is controlled by members of the Rho GTPase family, particularly Rac, 
RhoA, and CDC42 (77, 84). The activity of ARP2/3 is regulated by Rac and CDC42 
(72, 85). Myosin activity is regulated by phosphorylation of its myosin regulatory 
light chain (MRLC) at Thr18/Ser19 (86). Phosphorylation of MRLC is dependent on 
several protein kinases and phosphatases, most of which are downstream effectors of 
Rho GTPases (72). 
As initial cell adhesion and spreading occurs, Rac and CDC42 are activated at 
the cell leading edge to mediate the formation of actin-rich membrane protrusions 
(80). Rac and CDC42 probably have overlapping functions to enhance protrusion 
formation. Whereas the expression of activated CDC42 alone produces filopodia, and 
expression of Rac stimulates formation of broad lamellipodia (3), RhoA promotes cell 
contractility by increasing phosphorylation of MRLC (87). At later stages of cell 
spreading, RhoA activation is necessary for maturation of focal adhesions and 
retraction of the cell rear edge (13, 80).  
Two groups of molecules acting downstream of integrin outside-in signalling, 
guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs), 
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directly control Rho GTPase activity (80). Rho family GTPases are active when they 
are GTP-bound and inactive when bound to GDP. Activation is catalyzed by GEFs 
and inactivation is promoted by GAPs that stimulate the intrinsic GTPase activity of 
the Rho proteins. In one example of this pathway, integrin ligation and clustering lead 
to activation of tyrosine kinases FAK and Src, which phosphorylate and recruit the 
scaffolding protein p130Cas (88). Tyr phosphorylation of p130Cas recruits 
SH2-containing adaptor protein Crk, which in turn recruits or activates Dock180. 
Dock180 is a GEF for Rac and mediates GTP loading and membrane targeting of Rac 
(89, 90). Active Rac promotes protrusion at the leading edge of the cell via 
WASP/WAVE-dependent activation of the Arp2/3 complex (91). 
 
1.5.3 Integrin cytoplasmic tail-binding proteins 
Integrin cytoplasmic tails play a critical role in regulating cell adhesion and 
spreading. Integrin cytoplasmic tails serve as a scaffold for adhesion components 
which in turn recruit other additional components leading to adhesome assembly (92, 
93). Many binding proteins have been identified, but there are relatively few binding 
sites within αIIb and β3 cytoplasmic tails (47, 70, 71). For example, Src-family kinase 
Fyn (94), paxillin (95) and skelemin (96) can each bind to the membrane-proximal 
region of β3 cytoplasmic tails. The membrane-proximal region of β3 tails is also 
involved in the formation of the interface with αIIb tails in inactive integrins. Once 
integrins bind to their ECM ligands, unclasping the interface may unmask binding 
sites for these proteins and enable their recruitment (70).  
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1.5.3.1 Proteins linking integrins to the cytoskeleton 
Talin is the best-studied protein that is recruited by integrin cytoplasmic tails into 
adhesions. Talin contains a globular head and a long rod domain. The head domain is 
sufficient for integrin activation by binding to integrin cytoplasmic tails (28). The 
talin rod contains many functional domains, including domains responsible for dimer 
formation, a direct actin-binding site at the carboxy-terminus, a second 
integrin-binding site and several binding sites for vinculin (97). Talin accumulates at 
nascent adhesions which form within 15 minutes after cells are plated on the ECM 
(98). Microinjection of antibodies to talin or talin antisense RNA disrupts stress fibers 
and inhibits cell adhesion, spreading and migration (99). The ECM–integrin–
cytoskeletal linkage provides a migration force at the leading edge of a migratory cell. 
A previous study showed that the binding of talin to minimal complexes of ligated 
integrins is an early step in the formation of integrin-mediated ECM–cytoskeleton 
connections (100). After αVβ3 binding to fibronectin, a weak bond connecting 
fibronectin and cytoskeleton was established to provide the initial mechanical force 
(100). However, this bond was disrupted in fibroblasts deficient in talin expression 
(100). Reexpression of wild-type talin1, but not talin1 lacking the actin-binding site, 
restored the weak force (100).  
Other cytoskeletal proteins including filamin, α-actinin, myosin, and skelemin are 
reported to directly bind with β3 tails (70, 101). Filamin and α-actinin are also 
actin-binding proteins. Filamin has important roles for actin crosslinking and is 
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involved in cell spreading and motility by connecting integrins to the cytoskeleton (57, 
102). α-actinin is also an effective actin cross-linker (103, 104), and has essential roles 
in the assembly and maturation of nascent adhesions (105). 
Skelemin is another cytoskeletal protein that can interact with integrin 
cytoplasmic tails (33). Skelemin is a myosin-binding protein and was originally found 
to concentrate at the periphery of M-disc (the region in the middle of myosin bundles) 
in muscle cells (106, 107). In vitro studies mapped the skelemin binding site at the 
membrane proximal regions of αIIb and β3 tails (96). It is of interest that skelemin 
co-localizes with αIIbβ3 in newly formed adhesions, but does not appear to be present 
in focal adhesions (108). However, the significance of skelemin binding is not yet 
clear. 
 
1.5.3.2 FAK and Src: switching on integrin signalling 
FAK and Src are crucial mediators of integrin signalling pathways that regulate 
the activation of Rho-GTPases. Both of them are non-receptor tyrosine kinases and 
their recruitment to the integrin cytoplasmic tail is an early event in adhesion 
assembly and acts to initiate integrin outside-in signalling.  
The N-terminal domain of FAK binds to integrin-tail peptides in vitro (95). 
Ligand engagement and clustering of integrins results in rapid autophosphorylation of 
FAK at Tyr397, as well as several additional sites within the kinase and C-terminal 
domains (109). Phosphorylation at Tyr397 leads only to a limited activation of FAK, 
but it generates an SH2-mediated interaction with Src. This interaction enzymatically 
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activates Src by releasing autoinhibition imposed by the interaction between its SH2 
domain and the inhibitory phosphorylated tyrosine (Tyr529). Src in turn 
phosphorylates other tyrosine sites of FAK, leading to maximal activation of FAK 
(109, 110).  
FAK activation is closely associated with focal adhesion formation and cell 
migration (111). FAK-null fibroblasts exhibit enhanced paxillin phosphorylation and 
adhesion formation, suggesting FAK activity is essential for efficient focal adhesion 
turnover in cell migration (112). FAK inhibition could result in compromised cell 
mobility whereas enhanced FAK activity promotes cell migration (111).  
The Src family of kinases contains nine members; Src, Fyn, Yes, Lck, Hck, Blk, 
Fgr, Lyn and Yrk, where Src is considered to be a principle player in αIIbβ3-mediated 
signalling (3). Src constitutively associates with αIIbβ3 in platelets (113-115). The 
association is mediated by interaction of the SH3 domain of Src with the four terminal 
residues of the β3 tail, 759YRGT (115). This association is important for integrin 
functions. For example, disrupting the interaction of integrin αIIbβ3 with Src kinase, 
either by substitution of β3 Thr762 with Ala or by treatment with an RGT synthetic 
peptide into human platelets leads to decreased platelet spreading on fibrinogen (116, 
117). A “β3 (Δ760-762)” knock-in mouse strain was generated, which lacked RGT 
residues of β3 tails necessary for the interaction with Src, but retained residues 
necessary for talin-dependent fibrinogen binding. The mice had variably prolonged 
tail bleeding times. Their platelets showed reduced spreading after plating on 
fibrinogen (118).  
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Activity of Src is negatively regulated by a phosphorylated tyrosine residue 
(Tyr529), which binds to the SH2 domain of Src leading to a closed conformation and 
inactivation of Src. Csk (c-Src terminal kinase) is a negative regulator of Src kinases, 
acting by phosphorylating Tyr529 to maintain Src autoinhibition. Dephosphorylation 
by protein–tyrosine phosphatase (PTP) at Tyr529 and phosphorylation at Tyr418 leads 
to Src activation. In resting platelets, Src forms a complex with αIIbβ3 and Csk (113). 
Fibrinogen binding to αIIbβ3 leads to Csk dissociation from αIIbβ3, PTP-1B recruitment 
to this inhibitory complex to dephosphorylate Tyr529, and autophosphorylation at 
Tyr418 (113-115). The clustering of integrins brings Src molecules into close 
proximity, potentially promoting Src transactivation. Another possible mechanism of 
Src activation is via FAK. Upon autophosphorylation, FAK Tyr 397 constitutes a 
docking site for the Src SH2 domain and relieves the intramolecular, inhibitory 
interactions on Src to activate the protein (119). 
Src is required for integrin-mediated adhesion and spreading. Pharmacological 
and genetic inhibition of Src in a variety of cell types impaired adhesion, while 
exogenous expression of activated Src promoted cell adhesion and spreading (91). For 
example, in Src-deficient fibroblasts, cell spreading is inhibited on fibronectin or 
vitronectin. The defective spreading is rescued by re-expression of Src (120, 121). In 
a study using epithelial cancer cell lines as a model, elevation of Src expression and 
activation has been implicated in progression of cancer cells to metastatic cells, which 
is not linked to enhanced cell growth, but rather to enhanced cell attachment to ECM 
and assembly of adhesion complexes (122).  
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Src mediates Tyr phosphorylation of FAK, p130CAS, paxillin and other adhesion 
molecules (123, 124). Characterization of these proteins revealed that they are major 
components of integrin-dependent signalling pathways. As previously described, Src 
phosphorylates FAK leading to full activation of FAK, and Src and FAK function as a 
complex to initiate integrin downstream signalling (91). p130CAS and paxillin are 
scaffold proteins, in which the phosphorylation of their Tyr residues recruits and 
organizes signalling molecules. 
 
1.5.4 Physiological and pathological implications 
Platelets and αIIbβ3-expressing CHO cells adherent to fibrinogen are broadly used 
model systems to study cell adhesion and spreading. Upon activation by inside-out 
signalling, αIIbβ3 integrins on platelets are capable of binding to soluble fibrinogen to 
form a thrombotic clot. During this process, αIIbβ3 integrins not only mediate 
platelet-platelet interactions, but also transmit an array of signals into the platelets, 
inducing a series of coordinated events including platelet adhesion, shape change, 
spreading on fibrinogen or fibrin matrix and clot retraction (125). First, αIIbβ3 
adhesion to fibrin stimulates dramatic cell shape changes. Discoid platelets develop 
spike-like filopodia and lamellipodial extension to mediate full spreading over the 
damaged area and thus seal the vessel wall (88). The morphologic changes are 
associated with dynamic actin polymerization and reorganization. After platelets 
adhere and aggregate at the wound site, the next step is the retraction of clots through 
contractile forces generated by the platelet actomyosin network and to ‘shrink’ the 
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thrombus' size (125). Retraction of clots stabilizes platelet aggregates, restores blood 
flow and also draws the wound edges together during wound repair. αIIbβ3 outside-in 
signalling leading to cytoskeletal reorganization and development of contractile force 
is crucial for these processes (126).  
Tumor progression has been associated with altered integrin-mediated adhesion. 
To undergo metastasis, circulating tumour cells must attach to vascular endothelial 
cells or components of the vessel wall. They enter the blood flow to reach the target 
organs, and then colonize and grow in distant organs. Specific interactions of tumour 
cells with the favourable environments of distant organs help initiate and promote 
tumour metastasis and growth (127). Highly tumorigenic breast cancer cells 
expressing β1 and β3 integrin family members adhere rapidly to bone ECM, 
suggesting an important contribution of integrin-matrix interaction to the 
establishment of breast cancer cells in bone (128). Furthermore, integrin adhesion to 
the ECM provides the traction force necessary for tumour cell motility and invasion of 
distant organs (129). Intravenous inoculation of MDA-MB-231 transfectants 
overexpressing αvβ3 in animals increased bone metastasis when compared with the 
inoculation of mock-transfected cancer cells (130). Treatment of animals with 
antagonists of αvβ3 reduces bone metastasis (130, 131). Integrins also regulate ECM 
remodelling and protease activity such as matrix metalloproteinase (MMP), and 
support tumor cell proliferation in either adhesion-dependent or -independent 
mechanisms (129). 
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1.6 αIIbβ3 antagonism 
Excessive platelet aggregation is a key event in myocardial infarction and other 
thrombotic diseases. αIIbβ3 has become an attractive pharmacological target for 
antithrombotic therapy because of its importance in platelet aggregation. A number of 
αIIbβ3 antagonists have undergone clinical testing for their potential use as short-term 
and long-term cardiovascular therapeutics. In the 1990s, three intravenous αIIbβ3 
antagonists approved by the FDA were: abciximab, a mouse/human chimeric 
antibody fragment c7E3 Fab; eptifibitide, a snake venom disintegrin-derived cyclic 
peptide; and tirofiban, a RGD peptidomemetic. These inhibitors have been approved 
for and are widely used for treatment of patients with acute coronary syndromes 
(ACSs), and have especially benefited patients undergoing percutaneous coronary 
intervention (PCI). The major side effect of these agents is bleeding complications. 
Choosing an optimal dosing was a challenge, as the window between the 
therapeutically efficacious doses to prevent platelet aggregation and higher doses that 
can lead to bleeding is narrow (132).  
To achieve long-term suppression of platelet aggregation and to prevent 
cardiovascular diseases, orally active αIIbβ3 antagonists were developed. However, the 
clinical trials were disappointing, with lack of efficacy and increased mortality of 
patients with ACS (133). One potential contributing factor is the activating property 
of the αIIbβ3 antagonists. An early study in 1991 showed that RGD peptide binding 
could induce a high affinity fibrinogen-binding conformation of αIIbβ3 (integrin 
activation) and subsequent platelet aggregation (134). Several αIIbβ3 antagonists are 
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ligand-mimetics, suggesting they may possess partial agonist effects. The monoclonal 
antibody abciximab, when used at low concentrations, also demonstrated an intrinsic 
activating property, resulting in fibrinogen binding to αIIbβ3 and activation of platelets 
(135). Specific types of αIIbβ3 antagonists can augment agonist-induced release of 
α-granules, a marker of platelet activation (136). In fact, platelet activation has been 
reported in patients with ACS receiving oral αIIbβ3 antagonist at low concentrations 
(137). 
An alternative strategy is to target the intracellular events of integrin signalling. 
Mice harbouring the point mutation (L746A) in the β3 tail that selectively disrupted 
interactions only with talin were resistant to both pulmonary thromboembolism and 
thrombosis of the carotid artery, but exhibited limited bleeding (138). This study 
suggested that targeting of β3 integrin–talin interactions may have advantages over 
current αIIbβ3 antagonists due to a reduced risk of pathological bleeding. In addition, 
membrane permeable peptides corresponding to specific segments of the cytoplasmic 
tails of αIIb and β3 were shown to inhibit activation of αIIbβ3 (139-141). However, 
these intracellular approaches to inhibit αIIbβ3 are only in the early stage of 
development.  
 
1.7 Rational and hypothesis 
Integrin inside-out signalling increases the affinity of integrins for ECM ligands. 
Ligated integrins generate outside-in signalling that controls many critical 
intracellular changes. Both inside-out and outside-in signalling of αIIbβ3, the 
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predominant integrin expressed in platelets, is important to form a stable thrombus in 
vivo. Binding of fibrinogen by the extracellular domain of αIIbβ3 directly supports 
platelet-platelet interactions. Occupied αIIbβ3 integrins cluster and trigger outside-in 
signalling that stabilizes the aggregate and supports wound healing responses.  
The interaction of intracellular molecules with the integrin’s cytoplasmic domain 
regulates the integrin activation state and/or integrin outside-in signalling. There are 
particular amino acids or motifs in both α and β cytoplasmic tails of αIIbβ3 that serve as 
binding sites for intracellular binding partners. Their interactions could generate an 
activation signal that leads to conformational changes within the ligand binding site, 
resulting in the expression of a competent receptor. In addition, some interactions 
occur after ligand binding, and could influence outside-in signalling and regulate 
intracellular events, such as cytoskeleton reorganization, cell spreading and motility.  
Among the cellular proteins that can directly interact with integrin cytoplasmic 
domains, skelemin is of particular interest as it can bind with the membrane proximal 
regions of both αIIb and β3 tails and shows dynamic co-localization with αIIbβ3 in 
newly formed adhesions (96) (108). We hypothesize that skelemin is not involved in 
the regulation of integrin activation, but is an important modulator for integrin 
outside-in signalling and acts to fine-tune the cell spreading process together with 
other cytoskeletal proteins. 
In addition, both αIIb and αv integrin subunits can pair with β3 subunits to form 
functional receptors, and they also share the central-turn motif within their 
cytoplasmic tails. These characteristics reveal a possible convergence in the 
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regulatory control of αIIbβ3 and αVβ3. Previous studies showed the antagonistic effects 
of the turn motif peptide derived from αV tails. Here, it is hypothesized that the turn 
motif of αIIb tails is important for the regulation of integrin functions. The turn 
motif-derived peptide (αIIb peptide) may not only inhibit αIIbβ3-ligand engagement, but 
also target αv integrins. To explore this hypothesis, the modes of function of the αIIb 
peptide have been investigated. 
 
1.8 Specific aims 
1.8.1 Aim 1: Evaluate the contribution of skelemin-αIIbβ3 interaction to integrin 
bi-directional signalling 
To determine the functional consequences of these interactions on αIIbβ3 
bi-directional signalling, expression of αIIbβ3 on CHO cells was used to examine 
integrin inside-out and outside-in signalling. A series of stable CHO cell lines were 
established, which expressed mutant αIIbβ3 receptors where skelemin binding residues 
at the membrane proximal region of integrin tails were mutated by alanine 
substitution. Cell surface expression of receptors and integrin activation states of 
mutant cells were first examined by flow cytometry. Transfection of skelemin 
immunoglobulin C2 motifs 4-5 that contain the αIIbβ3-binding domain (skeC2) into 
wild-type and mutant cells was used to characterize whether skelemin is involved in 
the regulation of integrin activation. To study the effects of the skelemin-integrin 
interaction on integrin outside-in signalling, three major experimental techniques were 
used, cell adhesion, cell spreading, and activation of downstream signalling molecules. 
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Confocal microscopy experiments were employed to determine whether skelemin 
colocalizes with αIIbβ3 in wild-type and mutant cells. As talin contact sites on αIIbβ3 
overlap those of skelemin, the study of skelemin and talin colocalization with αIIbβ3 
also gives insights into whether the binding of the two proteins with integrin is 
mutually exclusive. 
 
1.8.2 Aim 2: Determine the mode of action of bioactive cell permeable 
cytoplasmic peptides 
There are activating and inhibitory functional motifs within the cytoplasmic tails of 
αIIbβ3. To test the capacity of cytoplasmic peptides to influence integrin activation on 
live cells, myristoylation of peptides was used as a means of efficient and 
non-invasive intracellular delivery. Our previous data indicate that the inhibitory 
capacity of the αV cytoplasmic tail peptide resides near the PP-turn motif. A peptide that 
derived from the turn motif of αIIb tails, its homologous αV peptide, and mutant peptide 
RPP/AAA and its scrambled form were synthesized. The functional properties of these 
peptides were examined in αIIbβ3-expressing CHO cells and the breast cancer cell lines, 
MDA-MB-435 and MDF-7. Cell adhesion assays and soluble ligand binding were 
performed to examine the inhibitory capacity and specificity of the peptides. To 
identify proteins that interact with the αIIb peptide, CHO cell lysates were 
immunoprecipitated with biotinylated peptides. Bound proteins were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), excised and 
subjected to mass spectrometry analysis. Furthermore, integrin downstream signalling 
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molecules in peptide-treated cells were examined with Western-blot. Whether the 
peptides still possess inhibitory capacity after ligand engagement was also 
investigated.  
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1 Cell culture 
CHO, MDA-MB-435 and MCF-7 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 100 units/ml 
penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% 
CO2 and 95% air. Stable αIIbβ3-expressing CHO cells were maintained in the presence 
of 400 μg/ml G418 (Geneticin) and 300 μg/ml hygromycin B and cultured in DMEM 
containing 10% FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin. Hek293 
cells were cultured in RPMI-1640 medium containing 10% FBS, 100 units/ml 
penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% 
CO2 and 95% air. 
 
2.2 Generation of stable αIIbβ3-expressing CHO cell lines 
The cDNAs for αIIb and β3 integrin subunits were cloned into pcDNA3.1 vectors 
harbouring neomycin and hygromycin resistance genes respectively. Mutations were 
carried out with the use of a site-directed mutagenesis strategy. All sequences were 
verified by DNA sequencing. CHO cells were transfected using Lipofectamine 
(Invitrogen Corp.) with the respective plasmids for both αIIb and β3 subunits according 
to the manufacturer’s instructions. At 48 hours after transfection, cells were harvested, 
diluted, and grown in fresh medium containing the selection reagent, G418 (600 
μg/ml) and hygromycin B (500 μg/ml). Selection media was changed every 2-3 days 
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until cell colonies formed. To obtain single cell clones, cells were treated with 
Trypsin-EDTA for 3 minutes before cells completely detached. Each colony was 
gently sucked up with a 200 μl pipette and immediately transferred to a 96-well plate 
containing the appropriate selection agent. After the cells grew to full confluence, they 
were harvested and their integrin expression levels were evaluated with flow 
cytometry. Briefly, 1×106 cells from each clone were trypsinized, suspended in PBS 
and incubated with 5 μg/mL anti-β3 antibody (CD61, Invitrogen) for one hour on ice, 
followed by labelling with goat anti-mouse Alexafluor 488-labelled antibody 
(Invitrogen), and then analyzed using flow cytometry The clones with the highest 
fluorescence intensity were chosen and grown in culture medium containing 400 
μg/ml G418 and 300 μg/ml hygromycin B. After 1-2 months growth, a stable cell line 
was generated with more than 95% β3 positive.  
 
2.3 Flow cytometry  
CHO cells were grown to 70–80% confluence and trypsinized. After quenching 
with complete medium, the cells were suspended in Tyrodes buffer containing 1 mM 
CaCl2, 1 mM MgCl2, 0.1% glucose and 0.1% BSA. To measure cell surface levels of 
integrin, CHO cells were incubated with 5 μg/mL anti-β3 mAb (Invitrogen) for one 
hour on ice. Cells were then washed, incubated with a secondary goat anti-mouse 
phycoerythryn (PE)-labelled antibody, and analyzed by flow cytomety. 
For PAC-1 binding, 5×105 cells were harvested and pre-treated with Tyrodes 
buffer containing 2 mM Ca2+, 200 μM Mn2+ or 2 mM EDTA at 37°C for 15 minutes. 
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Cells were then incubated with PAC-1 (10 μg/ml, Becton Dickinson) at room 
temperature for one hour, washed and then incubated with PE-labelled goat 
anti-mouse Ig (BD Biosciences) for one hour on ice. Cells were analyzed by flow 
cytometry. The mean fluorescence intensity was used to provide a measure of ligand 
binding affinity of integrins.  
To assess the effect of skelemin fragment expression on the integrin affinity state, 
cells were transiently transfected with green fluorescence protein (GFP) or 
GFP-skeC2 using Lipofectamine (as above). After 48 hours, cells were harvested and 
pre-treated with Tyrodes buffer containing 2 mM Ca2+, 200 μM Mn2+ or 2 mM EDTA 
at 37°C for 15 minutes. PAC-1 binding assays were carried out following the above 
method. An integrin activation index was used to compare integrin activation levels in 
GFP and GFP-skeC2 transfected cells for each mutant. The activation index was 
calculated using the following formula:  100×(FCa - FEDTA)/FMn, where FCa is the 
mean fluorescence intensity (MFI) of PAC-1 binding in the presence of Ca2+, FEDTA is 
the PAC-1 binding in the presence of EDTA, and FMn is the maximal PAC-1 binding 
in the cells treated with Mn2+. 
 
2.4 Cell adhesion assay 
The day before performing the cell adhesion assay, 96-well tissue culture plates  
were coated overnight at 4°C with 50 μl of 20 μg/ml fibrinogen, 5μg/mL vitronectin 
or heat-denatured 1% bovine serum albumin (BSA). Cells were grown to 70–80% 
confluence and detached with Trypsin-EDTA. After quenching the trypsin with 
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complete medium, cells were suspended in PBS. Cell number was counted on a 
coulter counter (Beckman Coulter) to obtain 5 × 104/well. Cells were incubated with 
cell permeable, non-fluorescent dye Calcein AM (10 μM Invitrogen) at 37°C for 30 
minutes in the dark. Calcein-AM is hydrolyzed by intracellular esterases to the cell 
membrane-impermeable green-fluorescent Calcein. Because the esterase activity is 
proportion to the number of viable cells, the fluorescence produced is used as a 
measure of the cell number. Labelled cells were washed twice and resuspended at 5 × 
105 cells/mL in Tyrode’s buffer containing 1 mM CaCl2, 1 mM MgCl2, 0.1% glucose 
and 0.1% BSA. The cells were then added to each well (4 × 105 cells in 100 μl) and 
incubated at 37°C for 30 minutes. Once cells were added, the cell fluorescence 
intensity for each well (FL1) was measured on the SpectraMax M2e microplate reader 
at 494 nm excitation and 517 nm emission wavelengths. After adhesion on ligand at 
37°C for 30 min, unbound or weakly attached cells were removed by washing twice 
with PBS. The cell fluorescence intensity after washing (FL2) was measured. Cell 
adhesion was quantified with the percentage of fluorescence intensity of attached cells 
relative to that of total cells (100 × FL2/FL1).   
For peptide treatment, the peptide stock solution (2.5 mM) was added into cell 
suspensions after cells were labelled by Calcein AM. Cells were treated with peptides 
for 20 minutes at 37°C. Then 100 μL of cell suspension (5 × 104/well), in the presence 
of peptides, was added to a ligand-coated 96-well plate. The cell fluorescence 
intensity before and after washing was measured and cell adhesion was quantified as 
described above. 
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For function-blocking cell adhesion experiments, labelled breast cancer cells 
were incubated with 10 μg/mL of each antibody for 20 minutes at room temperature. 
Then 100 μL of cell suspension (5 × 104/well) in the presence of antibodies was added 
to a ligand-coated 96-well plate. Three antibodies were used as function-blocking 
antibodies; αvβ3 (MAB1976, Millipore), αvβ5 (MAB1961, Millipore) and αvβ6 
(MAB2077Z, Millipore). The cell fluorescence intensity before and after washing was 
measured and cell adhesion was quantified as described above. 
 
2.5 Platelet aggregation assay 
Blood was drawn by venepuncture using 3.2% buffered sodium citrate as the 
anticoagulant. Platelet-rich plasma (PRP) was prepared by centrifugation at 150 g for 
15 minutes and used within 4 hours. The PRP was carefully removed and platelet poor 
plasma (PPP) was obtained by centrifuging the remaining blood at 1200 g for 
15 minutes. The platelet count of PRP was measured on a coulter counter (Beckman 
Coulter) and adjusted to 2 x 108 platelets/ml using PPP. PRP (450 μl) was transferred 
to siliconized glass aggregometer tubes. The aggregometer tubes were transferred to a 
560CA whole blood lumi-aggregometer (Chronolog Corp.) which measures the 
changes in light optical density for each sample. The PRP was warmed to 37°C for 
five minutes. In peptide post-treatment assay, platelet aggregation was initiated by the 
addition of ADP (10 μM) and epinephrine (EPI) (20 μM). Five minutes later, 50 μl of 
the test peptide or control peptide were added and the samples were monitored for an 
additional five minutes. In peptide pre-treatment assay, the PRP was treated with 50 
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μM peptides. Then ADP (10 μM) and EPI (20 μM) were added and platelet 
aggregation was monitored.  
 
2.6 Immunohistochemistry  
Falcon 4-well culture slides were treated with 1% SDS, rinsed with PBS and then 
coated with 20 g/ml of fibrinogen or 5 μg/ml vitronectin overnight at 4°C. Cells were 
seeded and adhered to culture slides for different times. Cells were fixed in 4% 
paraformaldehyde for 10 minutes, permeabilized by 0.2% (V/V) Triton X-100 for 10 
minutes, washed three times and blocked with 1% BSA in PBS. Filamentous actin 
(F-actin) was stained using Alexa Fluor 594 phalloidin (Invitrogen) for 30 minutes at a 
1:40 dilution, and visualized using fluorescence microscope. 
Focal adhesions were stained using an antibody to vinculin (hVin-1, Sigma) and 
then a fluorescein-conjugated secondary antibody. For visualization of integrin 
distribution, cells were fixed in 4% paraformaldehyde, incubated with β3-specific 
mAb (AP3, GTI Diagnostics) overnight at 4°C and then a fluorescein-conjugated 
secondary antibody for two hours. Permeabilization is not required for staining 
integrin receptors. For visualization of integrin and skelemin/talin colocalization, β3 
integrins were first stained as described above, and then talin (C-20, Santa Cruz) or 
skelemin (rabbit IgG from Dr. T. Ugarova) was stained with BD Cytofix/Cytoperm 
solution (BD Biosciences) following the manufacturer’s instructions. This sequential 
approach preserved the cell surface antigens during the intracellular staining.  
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2.7 Co-immunoprecipitation  
Wild-type and mutant CHO cells were transfected with GFP-skeC2 plasmids for 
48 hour, then harvested and allowed to adhere to fibrinogen-coated dishes for one 
hour at 37°C. Cells were solubilized with lysis buffer [20 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 1% Triton X-100, 1 mM CaCl2, 1 mM Phenylmethylsulfonyl Fluoride 
(PMSF), 100 μg/mL leupeptin, and 10 mM benzamidine] for one hour at 4°C. After 
centrifugation at 12,000 rpm (15 minutes, 4°C), the supernatant was collected as total 
cell proteins. Protein concentrations of lysates were determined via the bicinchoninic 
acid (BCA) assay (Sigma). Lysis buffer was added to make each sample up to a final 
volume of 600 μl, and contain equal amount of protein for each 
co-immunoprecipitation (600 μg to 1000 μg total proteins). The lysates were 
incubated with 2 μl anti-GFP serum (Invitrogen) for two hours at 4°C. The 
immunocomplexes were captured by incubation with 40 μl of Protein G-agarose 
overnight at 4°C and washed three times. The immunocomplex samples were boiled 
in 20 μl 3× sample loading buffer [New England Biolabs; 187.5 mM Tris-HCl, 6% 
sodium dodecyl sulphate (SDS), 30% glycerol and 0.03% phenol red] for 5 minutes. 
Samples were then frozen or prepared for Western blot analysis. 
 
2.8 Western-blot  
CHO cells were harvested, washed and suspended in Tyrodes buffer containing 1 
mM CaCl2, 1 mM MgCl2, 0.1% glucose and 0.1% BSA. Cells were allowed to adhere 
on fibrinogen-coated culture dishes for one hour at 37°C. The buffer was removed, 
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and cells were scraped from the tissue culture dish in cold PBS. Cell suspension was 
pooled, centrifuged, and the cell pellet was lysed for one hour at 4°C in 120 μl of lysis 
buffer (CelLyticTM M, Sigma) with protease inhibitor cocktail (Sigma) and protein 
phosphatase inhibitor (Millipore).  
After starving with FBS-free media for 12 hours, MDA-MB-435 cells were 
detached with Trypsin-EDTA. Trypsin was quenched with complete medium and cells 
were then resuspended in Tyrode’s buffer. Cells were incubated with 100 μM peptides 
at 37°C for 20 minutes, and plated on vitronectin-coated dish. After 1 hour to allow 
for adhesion at 37°C, floating cells as well as adherent cells were collected and lysed 
in lysis buffer (CelLyticTM M, Sigma) that contained protease inhibitors (Sigma) and 
protein phosphatase inhibitors (Millipore).  
Cell lysate was kept on ice for 1 hour, followed by centrifugation at 12,000 rpm 
(15 minutes, 4°C). Protein concentrations of supernatant were determined via BCA 
assay (Sigma) to make sure of equal protein loading. Total proteins (50-100 ug) were 
boiled for 5 minutes in 3× sample loading buffer (New England Biolabs, 187.5 mM 
Tris-HCl, 6% SDS, 30% glycerol and 0.03% phenol red) and resolved by 7.5% 
SDS-PAGE. Proteins were then transferred to nitrocellulose membrane (Whatman) 
with a semi-dry protein transfer apparatus (40 minutes at 240 mA). The membrane 
was blocked with 5% TBST (Tris-Buffered Saline and Tween 20) blocking milk [TBS 
(100 mM Tris-Cl pH 8, 150 mM NaCl), 0.01% Tween (v/v), 5% non-fat milk] for 30 
minutes at room temperature. 5% BSA in TBST was used to block membranes for 
detecting phosphorylated proteins. After blocking, membranes were incubated 
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overnight at 4°C with primary antibodies as follows: anti-pY416-Src (100F9, Cell 
Signalling), anti-Src (mAb327, Calbiochem), anti-β3 antibody (N20, Santa Cruz), 
anti-pY397 FAK (Santa Cruz), FAK (A-17, Santa Cruz), β-actin (Santa Cruz), 
phospho-Erk1/2 (197G2, Cell Signalling), and Erk1 (K-23, Santa Cruz).  
Primary antibody was removed and membranes were washed 4-5 times with 
TBST. Membranes were then incubated with secondary antibodies conjugated with 
horseradish peroxidase in 5% TBST blocking milk for two hours at room temperature. 
Membranes were then washed with TBST three times. Proteins were detected by 
rinsing membranes with a 1:1 dilution of Chemiluminescence Substrate (PerkinElmer) 
and exposing them to X-ray film (Santa Cruz).  
 
2.9 Peptide synthesis 
Peptides were synthesized on an Applied Biosystems 433A peptide synthesizer at 
0.25 mM scale using fourfold excess of 9-Fluorenylmethyl-carbonyl (Fmoc)-amino 
acids relative to the p-alcoxybenzyl-alcohol resin (Wang resin). Coupling was 
performed with 0.5 M N-Hydroxybenzotriazole/O-Benzotriazole-N,N,N’,N’- 
tetramethyl-uronium-hexafluoro-phosphate (HOBt/HBTU).  
The myristoylated peptides were synthesized by a covalent linkage of myristic 
acid to the N-terminal amino group of the lysine residue. Briefly, 1 ml 
N,N-Diisopropylethylamine (DIEA) in dimethylformamide (DMF) was added to the 
peptide-resin vessel and mixed for 5 minutes. The resin was drained and washed with 
DMF two times. 520 mg myristic acid was dissolved in dichloromethane (DCM) with 
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heating (at about 40 °C, 10-15 seconds) and vortexing. Repeat heating and vortexing 
process until fully dissolved. Then 460 mg N,N'-Dicyclohexylcarbodiimide (DCC) 
dissolved in DMF were added to the myristic acid solution. After 5 minutes, the 
mixture of myristic acid and DCC was added to the peptide-resin vessel, with 
myristoylation was carried out under constant shaking. Myristoylation was monitored 
by the use of ninhydrin test (Applied Biosystems), which yields deep-blue or purple 
color by reacting with primary amines when the N-termini of peptides are not 
myristoylated. Completion of myristoylation was shown by a colorless negative 
result. 
The myristoylated peptides on resin were washed and dried under high vacuum 
over night. The side-chain protecting groups on peptides were removed and peptides 
were cleaved from the resin by treatment with 10 ml trifluoroacetic acid 
(TFA):phenol:water:triisopropylsilane (TIPS) (88:5:5:2) for 4 hours. 
Crude peptides were purified by semi-preparative reversed phase 
high-performance liquid chromatography (HPLC) on a C18 column (C18 is a 
silica-based column with octadecyl carbon chains bonded on silica). Purified peptides 
were analyzed on a Varian ProStar HPLC using a C18 column, 250 × 4.6 mm. 
The biotin group was labelled on the amino group of Lys side chain. Briefly, 20 
mg myristoylated peptide was dissolved in 4 ml DMF. 175 μl DIEA was added to the 
peptide solution. Immediately before use, a solution of N-Hydroxysuccinidobiotin 
(NHS-Biotin) was prepared by dissolving 19 mg NHS-Biotin in 500 μl DMF. The 
NHS-Biotin solution was then added to the peptide solution. The reaction mixture was 
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protected from light and stired with a magnetic stirring bar. After 4 hours of reaction, 
biotinylated peptides were purified by semi-preparative reversed phase HPLC on a 
C18 column. 
The molecular weight of each peptide was confirmed by mass spectrometry and 
the purity was over 98%, as assessed by analytical HPLC (Figure 2.1A and B). The 
peptides were dissolved in 10% ethanol with pH 7-9 adjusted with 1M KOH. Cellular 
uptake and intracellular distribution of bio-peptides was studied by 
immunocytochemistry. The immunofluorescence microscopic image of the bio-αv 
peptide distribution is representatively shown in Figure 2.1C. 
 
2.10 Peptide electrophoresis on 20% SDS-PAGE gel 
The electrophoretic mobility of peptides was assessed by using a 20% SDS-PAGE 
gel. Gels were cast and run using the BioRad Mini-PROTEAN® Electrophoresis 
system (BioRad). To prepare 6 ml separating gel solution, 3 ml 40% acrylamide, 2 ml 
3 M Tris-Cl (pH 8.45), 60 μL 10% SDS(w/v), 200 μL H2O and 634 μL glycerol were 
mixed. 50 μL ammonium persulfate (APS) and 5 μL tetramethylethylenediamine 
(TEMED) were added, mixed gently and then immediately poured between two glass 
plates immobilized in a casting apparatus. The gel solution was topped with a thin 
layer of ethanol to ensure a level surface. To prepare the stacking gel, 0.26 ml 40% 
acrylamide, 0.62 mL 3 M Tris-Cl (pH 8.45), 20 μL 10% (w/v) SDS and 1.62 mL H2O 
were mixed. Once the separating gel is solidified, the ethanol was poured off and a 
stacking gel solution was poured on top of the separating gel and a gel comb was 
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Figure 2.1 Purity and cellular distribution of the αv peptide. (A, B) Histograms 
show HPLC tracings of the αv (A) and bio-αv (B) peptides. The solvent was aqueous 
acetonitrile with 0.1% TFA run at a flow rate of 1 ml/min. The gradients were 1–60% 
acetonitrile over 60 min. Detection was light absorption at 215 nm, where the peptide 
bond absorbs. (C) Cellular distrubution of the bio-αv peptide. The αV peptide was 
biotin labelled. After treated with bio-αv for 30 minutes, MCF-7 cells were fixed in 4% 
paraformaldehyde for 10 min, and permeabilized by 0.2% (V/V) Triton X-100 for 5 
min. Peptide was then stained by PE-labelled avidin and visualized by 
immunofluorescence microscope. The picture showed that most peptides were 
accumaulated on the plasma membrane, as indicated by the blue arrow. 
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inserted in the stacking gel. Before electrophoresis, 1 μg peptide sample was 
incubated with 3X SDS sample buffer (New England Biolabs; 187.5 mM Tris-HCl, 6% 
SDS, 30% glycerol and 0.03% phenol red, 0.125 mM DTT) at 70°C for 10 min. The 
gel was run in tricine-SDS running buffer (100 mM Tris, 100 mM Tricine, 0.1% SDS) 
at a constant 150 Volts until desired peptides or proteins were sufficiently separated. 
Peptide bands were visualized by staining with 0.025% (w/v) Coomassie Blue R250. 
Briefly, the gel was placed in fixative solution (40% methanol, 10% acetic acid) and 
equilibrated for 30 minutes. Gels were stained in stain solution (0.025% (w/v) 
Coomassie Blue R250, 10% acetic acid) for one hour and distained in 10% acetic acid 
three times for 15 minutes or until the desired background was achieved. 
 
2.11 Mn2+ stimulated fibrinogen binding assay  
αIIbβ3-transfected CHO cells were harvested, and suspended at 1×107/ml in 
Tyrodes buffer containing 1 mM CaCl2, 1 mM MgCl2, 0.1% glucose and 0.1% BSA. 
100 μl cell suspension was treated with different concentrations of each peptide for 15 
minutes at 37°C, and stimulated with 400 μM Mn2+ for another 15 minutes. 5 μl 1.5 
mg/ml Alexafluor 488-labelled fibrinogen (Molecular Probes) was then added to the 
cell suspension and incubated for 45 minutes at room temperature. Cells were washed 
twice with fibrinogen binding analyzed by flow cytometry. 
In addition to flow cytometry, CHO cells prepared as above were analyzed by 
immunocytochemistry. Cell cultures were fixed with 4% paraformaldehyde for 10 
minutes and stained with anti-β3 antibody (AP3, GTI. Diagnostics), followed by the 
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addition of PE-labelled goat anti-mouse antibody. Cells in mounting media were 
plated on coverslips and visualized by confocal microscopy. 
 
2.12 Co-immunoprecipitation with streptavidin-coated Dynabeads 
25 μl Streptavidin-coated Dynabeads (M-280, Invitrogen) were washed in PBS 
three times, re-suspended and incubated for 2 hours at room temperature with 
constant rotation with or without 20 μg biotinylated peptides. Beads were washed four 
times in PBS. αIIbβ3-transfected CHO cells were harvested and lysed in lysis buffer 
(CelLyticTM , sigma) with protease inhibitor (Sigma). 120 μl cell lysate was diluted 
with 450 μl PBS, and incubated with activated beads at 4°C overnight. Unbound 
proteins were removed by extensive washing in a buffer (20 mM tris pH 7.4, 1% 
triton-100, 50 mM NaCl, 1 mM Ca2+, 1 mM Mg2+). Associated proteins were eluted 
by boiling for 8 minutes in SDS sample buffer with DTT. Proteins were separated by 
7.5% SDS-PAGE and visualized within the gel using silver staining (ProteoSilver™ 
Silver Stain Kit, Sigma). The gel bands of interest were cut out, trypsinized and the 
proteins within them were identified by mass spectrometry. 
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CHAPTER 3 
SKELEMIN IN αIIbβ3 –MEDIATED CELL SPREADING 
 
This chapter has been published as a paper in  
Biochemistry (2013) 52: 681–689  
Contents of this chapter have been adapted / reproduced from the published article 
with permission from the journal “Biochemistry”  
 
3.1 Introduction 
The role of integrin in cell adhesion, spreading and migration relies on its 
connection to the cell cytoskeleton. A numbers of proteins are recruited directly or 
indirectly via adaptors to the cytoplasmic tails of integrin, for example, talin, filamin, 
α-actinin and myosin (71). These proteins promote integrin-actin cytoskeleton linkage 
which influences reorganization of the actin cytoskeleton and generates traction forces 
necessary for cell spreading and migration. Skelemin was reported to bind to the β1 
and β3 cytoplasmic tails via yeast two-hybrid assays (142). Skelemin is a cytoskeletal 
protein first identified in the periphery of the sarcomeric M-line of myosin thick 
filaments in striated muscles (143). In muscle cells, skelemin cross-linked myosin 
filaments to maintain the thick filament lattice (144), and to serve as a linker between 
M-band and intermediate filaments through a desmin binding domain (107). Skelemin 
is a myomesin isoform and belongs to a member of a family of myosin associated 
proteins. Skelemin and myomesin are encoded by the same gene but alternative 
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splicing gives rise to the insertion of a serine/proline-rich domain in the center of 
skelemin (145). Recent studies have confirmed the presence of skelemin in 
non-muscle cells, such as platelets and CHO cells (108, 142, 146). In addition, after 
adhering to immobilized ligand fibrinogen, skelemin can interact and co-localize with 
integrin αIIbβ3 at the initial stage of cell spreading, suggesting that skelemin serves as 
a cross-linker between integrin and the myosin cytoskeleton in non-muscle cells (108, 
142, 146). 
Skelemin is one of very few proteins reported to bind to both the αIIb and β3 
cytoplasmic tails of an integrin (96, 146). It contains five repeats of fibronectin type 
Ш motifs and seven repeats of immunoglobulin superfamily C2-like motifs (107). 
The primary interaction of skelemin with αIIbβ3 involves the skelemin 
immunoglobulin C2 motif 5 and the membrane proximal regions of the αIIbβ3 
cytoplasmic tails, while there is an additional low affinity contact between the 
skelemin immunoglobulin C2 motif 4 and the C-terminus of β3 tails (96, 142). 
However, the functional significance of skelemin-integrin interactions has not been 
fully explored. In this chapter, integrin affinity state, outside-in signalling and related 
functions in CHO cells overexpressing mutant integrins lacking the capacity of bind 
skelemin were investigated. Dr. Haas and his collaborators previously identified the 
critical residues in the αIIb and β3 tails involved in skelemin binding (146). Here, 
alanine substitutions were introduced at Arg995, Arg997 and Leu1000 in the αIIb tail 
region, and Lys716 and His722 in the β3 tail region (Figure 3.1). Stably expressed 
single, double or triple mutations in CHO cells were established, namely R995A, 
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R997A, R995A/R997A, L1000A, R995A/R997A/L1000A, K716A, H722A, and 
R995A/R997A/K716A. Integrin-mediated cell adhesion, cell spreading, activation of 
FAK and Src were investigated, and the distribution of αIIbβ3, skelemin and talin were 
measured in the protrusions of the cell leading edge. 
 
3.2 Results 
3.2.1 Integrin expression  
The expression of wild-type and mutant integrin was assessed by flow cytometry 
using a β3-specific antibody (Figure 3.1). The percentage of cells expressing αIIbβ3 
receptors in the mutant cell lines were comparable to those of wild-type cells, except 
for K716A which had only 70% of cells expressing comparable amount of integrins.  
 
3.2.2 Association of skelemin with mutant integrins  
Experiments were then performed to confirm that our mutations resulted in a 
decreased association of skelemin with the expressed integrins. In cells, skelemin is 
present as either a soluble cytoplasmic protein or as an insoluble cytoskeletal-bound 
protein. The relative abundance of soluble endogenous skelemin in our cell lines was 
very low and therefore the interaction between endogenous skelemin and αIIbβ3 was 
difficult to evaluate by co-immunoprecipitation and western blot. Therefore, to 
overcome this problem, co-immunoprecipitation experiments were performed using 
recombinant GFP-skeC2 fusion protein (skeC2: skelemin immunoglobulin C2 motifs 
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Figure 3.1 Amino acid sequences of αIIb and β3 cytoplasmic tails and cell-surface 
expression levels of wild-type and mutant αIIbβ3 CHO cells. (A). Amino acid 
sequences of αIIb and β3 cytoplasmic tails. Residues targeted for alanine substitutions 
are underlined and sequence numbers displayed. (B). Cell-surface expression levels of 
CHO cells transfected with wild-type and mutant αIIbβ3. Cells were harvested, and 
incubated with Tyrode-Hepes Buffer alone (grey line) or with an anti- β 3 antibody 
(black line). A PE-labelled secondary antibody was used to detect bound anti-β3 
antibody and flow cytometry analysis was performed in Tyrode-Hepes buffer. Cells 
incubated only with the secondary antibody (grey line) were used as controls. 
Histograms were generated using FlowJo. The data are representative of three 
separate experiments. 
52 
 
4-5 that contain the αIIbβ3-binding domain). Wild-type, R995A/R997A/L1000A, 
H722A and K716A cells were transiently transfected with plasmids of GFP-skeC2 or 
GFP alone (control). After 48 hours of transfection, cells were harvested and allowed 
to adhere to immobilized fibrinogen for 1 hour. Cell lysates were subjected to 
immunoprecipitation with antibodies against GFP, then western blot analysis (Figure 
3.2). Two GFP-immunoreactive proteins were detected, GFP (～27 kD) and the 
GFP-skeC2 fusion protein (～90 kD). An apparent MW of 90 kD is consistent with 
the predicted size of the fusion protein. A long transfer time (40 min) was used to 
ensure sufficent transfer of proteins from the gel to the nitrocellulose membrane under 
semi-dry transfer conditions. Low MW proteins in a pre-stained protein ladder passed 
through the membrane, which indicated that some GFP proteins (～27 kD) might be 
also over-transferred, leading to decreased band intensity (Figure 3.2). 
Immunoblotting with an anti-β3 antibody revealed that β3 proteins were 
co-immunoprecipitated with GFP-skeC2, but not with GFP (Figure 3.2). In 
comparison to wild-type cells, there appeared to be a decrease in the amount of αIIbβ3 
co-immunoprecipitated with R995A/R997A/L1000A, H722A and K716A mutated 
integrins. Thus, we confirmed that the mutations did result in a decrease association 
of skelemin with αIIbβ3. 
 
3.2.3 Integrin affinity for ligands 
The membrane proximal regions in the integrin cytoplasmic domains are 
important for integrin activation modulation, and point mutations within this region 
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Figure 3.2 Association of GFP-skeC2 with αIIbβ3. Wild-type, R995A/R997A/ 
L1000A, H722A and K716A mutant cells were transfected with GFP-skeC2 plasmids 
for 48 hour, and then allowed to adhere to immobilized fibrinogen for one hour. Cell 
lysates were immunoprecipitated with anti-GFP. Western blot analysis using anti-β3 
antibody revealed a decreased association between GFP-skeC2 and the mutant αIIbβ3 
receptors compared to wild-type αIIbβ3. 
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could enhance the affinity for integrin ligands and promote constitutive signalling (39, 
147). To assess the activation state of αIIbβ3, flow cytometry was used to study αIIbβ3 
binding to PAC-1, which recognizes the conformationally active form of αIIbβ3 (Figure 
3.3). αIIbβ3 binding to its ligand requires divalent cations  (Ca2+ or Mg2+). Optimal 
αIIbβ3 binding to ligands occurs in the presence of Ca2+ at a concentration of 1-2 mM, 
a physiological Ca2+ concentration in human plasma (148). In the current study, 2 mM 
Ca2+ was used. EDTA chelates either Ca2+ or Mg2+ and is used as an inhibitor of 
integrin ligand binding. PAC-1 binding in the presence of EDTA represented 
non-specific ligand binding, which was subtracted from the total binding (in the 
presence of divalent cations) to yield specific binding. Low and negligible PAC-1 
binding was observed in the presence of EDTA, suggesting that Ca2+-mediated PAC-1 
binding was specific (Figure 3.3C). In the presence of Ca2+, wild-type αIIbβ3 expressed 
in CHO cells was in the resting state, while R995A, K716A and 
R995A/R997A/L1000A cells bound significant levels of PAC-1, showing that the 
three mutants are active (Figure 3.3A). These data are consistent with previous 
mutational studies (39, 149), suggesting that the residues K716 and R995 within β3 
tails are involved in the regulation of αIIbβ3 activation.  
Mn2+ has a higher affinity for integrins than Ca2+ or Mg2+. It strikingly increases 
the ligand binding affinity of almost all integrins by binding to integrins and inducing 
conformational changes of the integrin ectodomain from a bent to an extended and 
active state (150). Therefore, Mn2+ has been widely used as a positive control for 
integrin activation. PAC-1 binding under the condition of Mn2+ treatment
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Figure 3.3 PAC-1 binding in the presence of metal ions. (A) PAC-1 binding in the 
presence of Ca2+. Cells treated with 2 mM Ca2+ or 2 mM EDTA were incubated with 
PAC-1, washed, incubated with a PE-conjugated secondary antibody, and analyzed by 
flow cytometry. Binding was expressed as mean fluorescence intensity (MFI) of 
PAC-1 staining in the presence of Ca2+ minus that obtained in the presence of EDTA. 
The data represent the mean ± S.E. of three separate experiments. (B) PAC-1 binding 
in the presence of Mn2+. (C) PAC-1 binding in the presence of EDTA. Binding was 
expressed as MFI of PAC-1 staining in the presence of 200 μM Mn2+. The data 
represent the mean ± S.E. of two separate experiments. 
 
was also tested (Figure 3.3B). Generally, Mn2+ was able to activate wild-type and 
mutant αIIbβ3 leading to a much higher level of PAC-1 binding. However, Mn2+ did 
not maximally activate αIIbβ3 integrin as Mn2+-induced PAC-1 binding in wild-type 
cells was still significantly lower than that of K716A cells treated with Ca2+ alone. 
Even though K716A and R995A/R997A/L1000A were in a activation state, Mn2+ had 
an additional activating effect for these mutants and enhanced PAC-1 binding 3-4 fold 
compared to wild-type αIIbβ3. These results suggest that amongst all the mutants, 
R995A, K716A and R995A/R997A/L1000A exhibited partial activation in the 
presence of Ca2+, but that in the presence of Mn2+ K716A and R995A/R997A/L1000A 
had higher maximal activation than that of wild-type αIIbβ3. 
 
3.2.4 Transfection with skeC2 did not affect the integrin affinity states 
To assess whether skelemin binding is responsible for activation of αIIbβ3, effects 
of exogenous skelemin overexpression on integrin activation were investigated by 
two-color flow cytometry (Figure 3.4). In this assay, wild-type and mutant cells were 
transiently transfected with either GFP-tagged skeC2 or GFP alone. Cells were 
harvested 48 hours after transfection, incubated with PAC-1 and then stained with 
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Figure 3.4 SkeC2 did not change integrin activation states in GFP-skeC2 
transfected wild-type or mutant cells. Cells were transiently transfected with 
vectors encoding GFP or GFP-skeC2. After 48 h, cells were harvested and analyzed 
by two-color flow cytometry for binding of PAC-1 binding. Integrin activation index 
was used to compare integrin activation levels in GFP and GFP-skeC2 transfected 
cells for each mutant. The activation index was calculated using the formula described 
in Materials and Methods. The data represent the mean activation index ± S.E. of 
three separate experiments. The difference of activation index in GFP or GFP-skeC2 
transfected cells was not statistically significant for any of the skelemin mutants using 
one-way ANOVA (P<0.05). 
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PE‐labelled secondary antibody. To study successfully transfected cells, GFP-positive 
cells were gated for further analysis of PE staining using flow cytometry. The 
percentage of PE-positive cells in the population of GFP-positive cells was assigned 
as the PAC-1 binding level in each sample. To study the effect of skeC2 transfection 
on integrin activation, PAC-1 binding levels in the presence of Ca2+, EDTA or Mn2+ 
were studied. Therefore, integrin activation can be quantified as an activation index, 
100×(FCa - FEDTA)/FMn, where FCa is the MFI of PAC-1 binding in the presence of 
Ca2+, FEDTA is the PAC-1 binding in the presence of EDTA, and FMn is the maximal 
PAC-1 binding in the cells treated with Mn2+. As shown in Figure 3.4, cells 
expressing either wild-type αIIbβ3 or the mutants, R995A/R997A and H722A, 
GFP-SkeC2 expression did not enhance PAC-1 binding. Similar results were also 
obtained with the three active mutants, R995A, K716A and R995A/R997A/L1000A. 
For each version of αIIbβ3 integrin, no statistically significant differences were found 
between cells expressing GFP-SkeC2 and GFP in their ability to bind PAC-1 (P<0.05). 
Thus, skelemin expression did not appear to alter the affinity state of αIIbβ3, suggesting 
that skelemin is not involved in αIIbβ3 activation. 
 
3.2.5 Adhesion to immobilized fibrinogen  
The strength of cell adhesion to ECM not only depends on integrin expression 
level and integrin affinity, but also relies on integrin-mediated cytoskeleton linkages. 
Previous studies demonstrated that skelemin and integrin association was an early 
response to integrin occupancy and clustering, being initiated between 30 minutes to 
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two hours after cell adherence. If their association is essential for linking ECM to the 
cell cytoskeleton, mutant cells may show decreased cell adhesion to ECM. Therefore 
we compared the capacity of the wild-type cells and cells expressing mutant integrins 
to adhere to fibrinogen over a 30 minute time period (Figure 3.5). Cells were labelled 
with fluorescent dye Calcein AM so that the fluorescence intensity of cells was 
directly proportion to the number of viable cells in each treatment. Fluorescently 
labelled cells were allowed to adhere to fibrinogen-coated microplates. After washing, 
adherent cells were counted as a percent of the number of total cells added. 
Non-specific cell adhesion was low, as less than 5% cells adhered to BSA-coated 
wells for all cell lines tested. Cell adhesion to fibrinogen was αIIbβ3–mediated, as 
adhesion of wild-type cells was 3 fold higher than that of mock-transfected cells. As 
shown in Figure 3.5, cell attachment of R995A, R995A/R997A, 
R995A/R997A/L1000A, K716A, H722A, and R995A/R997A/K716A to fibrinogen 
was higher than that of wild-type cells, while R997A and L1000A cell adhesion were 
comparable. The R995A and K716A mutations showed the strongest cell adhesion, in 
agreement with their active state as assessed by PAC-1 binding. In general it appears 
that disruption of the skelemin binding sites in αIIbβ3 did not impair stable cell 
adhesion, suggesting that skelemin-αIIbβ3 interaction may not be essential for the 
linkage of integrin to the cell cytoskeleton.  
 
3.2.6 Cell spreading and membrane protrusions 
Integrins and their associated proteins form focal adhesions in cultured cells, 
60 
 
which link integrin clusters to the actin cytoskeleton and initiate actin assembly into 
stress fibers. Here, stress fibers were stained with fluorescence-labelled phalloidin 
after cell adhesion to fibrinogen-coated coverslides for one hour (Figure 3.6). Normal 
CHO cells lacking αIIbβ3 expression were still round at this time point, whereas 
wild-type and mutant αIIbβ3 transfected cells were spreading and already displaying 
 
 
Figure 3.5 Adhesion of mutant cells to immobilized fibrinogen. Calcein-AM 
labelled cells were plated on 20 μg/ml fibrinogen coated wells and total cell 
fluorescence were measured on a fluorescence microplate reader. After 30 minutes 
adhesion in Tyrode’s buffer, weakly and non-adherent cells were washed away and the 
fluorescence of remaining cells was measured. Cell adhesion, the percent of adherent 
cells to total cells added, was calculated using the formula described in Materials and 
Methods section 2.4. Cell adhesion to BSA-coated wells was subtracted as 
background. The data represent the mean ± S.D. of three separate experiments. 
**P<0.01 compared to wild-type cells using student’s t-test.  
 
61 
 
 
 
Figure 3.6 Effect of αIIbβ3 mutations on the actin cytoskeleton. (A) After spreading 
on fibrinogen-coated wells for one hour, cells were fixed, permeabilized and stained 
with rhodamine phalloidin to detect F- actin. a: CHO; b: wild-type; c: R995A; d: 
R997A; e: R995A/R997A; f: R995A/R997A/L1000A; g: K716A; h:H722A; and i: 
R995A/R997A/K716A. Scale bar: 10 μm. (B) Quantitative analysis of cell spreading. 
The area of each cell was measured using ImageJ analysis software. The mean area of 
wild-type cells was normalized to 1. Error bars are standard deviations. *P<0.05 
compared to wild-type cells using student’s t-test. 
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strong formation of stress fibers. There was also obvious formation of lamellipodia 
and filopodia within both wild-type and mutant cell lines. Quantitative measurements 
of cell areas clearly showed that mutant cells R995A/R997A/L1000A, K716A, 
H722A and R995A/R997A/K716A exhibited a greater extent of cell spreading (Figure 
3.6B). We also stained cells with anti-β3 antibody (AP3) and observed formation of 
many αIIbβ3-based focal adhesions, lamellipodia and filopodia at the leading edges of 
the mutant cell lines (data not shown). Taken together, these results demonstrate that 
defective binding of skelemin to αIIbβ3 does not disrupt actin cytoskeleton 
organization, or membrane protrusion formation and cell spreading, suggesting that 
other cytoskeletal proteins are capable of performing some of the functions performed 
by skelemin. Thus, different cytoskeletal proteins may act in unison to maintain 
integrin-cytoskeleton linkages.  
 
3.2.7 Src and FAK activation downstream of integrin signalling  
The increased cell adhesion ability and higher spreading level observed in some 
mutations suggested that there was an upregulation in integrin-downstream signalling. 
Therefore, activation of FAK and Src, two important tyrosine kinases in integrin 
signalling that are required for efficient adhesion and spreading of cells on integrin 
ligands were examined. After cell adherence to fibrinogen in Tyrodes buffer for one 
hour, activation of Src and FAK were assessed by probing the phosphorylation levels 
of pY416-Src, the positive regulatory autophosphorylation site of Src (151), and 
pY397-FAK, the major site of tyrosine phosphorylation on FAK (152). Western blot 
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Figure 3.7 Effect of wild-type and mutant αIIbβ3 on Src and FAK signalling. Cells 
were allowed to spread on fibrinogen-coated plates for one hour, lysed and total cell 
extracts were subjected to SDS-PAGE. Blots were probed using antibodies against 
pY416-Src, Src, pY397-FAK, β3-integrin, GAPDH and β-actin. (A) Analysis of 
pY416-Src and pY397-FAK in total cell lysates was done on wild-type and mutant 
cells. (B) Analysis of pY416-Src in total cell lysates was done on wild-type αIIbβ3–
expressing cells and mock-transfected cells. 
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Figure 3.8 Comparable or increased pY416-Src levels in mutant αIIbβ3- 
transfected cells. Western blot analysis of pY418-Src in wild-type and mutant cells 
was repeated in three independent experiments. The graph shows densitometric 
quantification of pY416-Src/β-actin. Band density was measured by Quantity One 
software and normalized to the β-actin protein level. The ratio of pY416-Src/β-actin 
in wild-type cells was assigned as 1. K716A and H722A cells showed significantly 
increased pY416-Src/β-actin levels compared with wild-type cells using student’s 
t-test, but the Kruskal–Wallis test revealed no significant difference between mutant 
and wild-type cells (P<0.05).  
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analysis of pY416-Src and pY397-FAK showed that comparable or potential higher 
levels of pY416-Src were observed in mutant cells compared to wild-type cells. 
However, there were no differences in cellular levels of pY397-FAK between mutant 
and wild-type αIIbβ3-expressing cells (Figure 3.7A). 
To study the effects of αIIbβ3-expression on Src activation, pY416-Src levels in 
wild-type αIIbβ3 and mock transfected cells were examined. As shown in Figure 3.7B, 
wild-type αIIbβ3-transfected cells had increased levels of the active form of Src 
(pY416-Src) than mock-transfected cells when they were plated on fibrinogen. These 
results suggested that the transfected αIIbβ3 integrins and their binding to ligands 
attribute to elevated levels of pY416-Src.  
Western blot analysis of pY416-Src in different mutant cells was repeated and the 
blots were quantified as shown in Figure 3.8. Bands were quantified by Quantity One 
software and normalized to the β-actin protein level. The levels of pY416-Src in 
K716A and H722A cells were slightly elevated compared with wild-type cells, which 
were in good agreement with their increased cell spreading. 
 
3.2.8 Effect of overexpression of skeC2 on cell spreading 
Previous studies have demonstrated that introduction of skeC2 into wild-type 
cells caused spread cells to round up (108, 142). The similar experiment was 
performed in Hek293 cells. Hek293 cells were transiently transfected with αIIbβ3, 
GFP-skeC2 or GFP individually and in combination, and harvested 48 hour after 
transfection. Transfected cells were allowed to adhere on fibrinogen-coated slides for 
two hours, then fixed and stained with anti-β3 antibody. As shown in Figure 3.9, the 
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Figure 3.9 Hek293 cells co-transfected with αIIbβ3 and GFP-SkeC2 show 
inhibited cell spreading on fibrinogen. Subconfluent Hek293 cells were transfected 
with αIIbβ3, GFP-skeC2 or GFP individually and in combination, and harvested 48 
hour after transfection. Cells were allowed to adhere for 2 hours on fibrinogen-coated 
slides, then fixed and stained with anti-β3 antibody and PE-labelled secondary 
antibody. GFP and αIIbβ3 expression were observed with confocal microscopy. Scale 
bar: 50 μm. 
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transfection of Hek293 cells with GFP-skeC2 inhibited αIIbβ3-mediated cell spreading. 
However, the inhibitory effect only occurred when the expression amount of 
GFP-skeC2 was relative high. 
The effect of overexpression of skeC2 on spreading in mutant αIIbβ3-transfected 
CHO cells was also investigated (Figure 3.10). Wild-type, R995A, 
R995A/R997A/L1000A, H722A and K716A cells transiently transfected with 
GFP-skeC2 or GFP were re-plated on fibrinogen, and observed by GFP 
immunofluorescence two hours after spreading (Figure 3.10). Wild-type cells 
transfected with GFP-skeC2 failed to spread on fibrinogen compared to transfection 
with GFP alone. A similar result was obtained in R995A cells. However, GFP-skeC2 
transfection had less effect on the spreading of R995A/R997A/L1000A, H722A and 
K716A cells. Notably, R995A/R997A/L1000A, H722A and K716A cells with strong 
GFP-skeC2 expression (indicated as increased GFP fluorescence intensity) were still 
able to spread, suggesting that skeC2 expression had little inhibitory effect on cell 
spreading in these three mutant cell lines. 
Figure 3.11 shows a representative confocal microscopic image of transfected 
wild-type and R995A/R997A/L1000A cells that were stained with anti-β3 antibody 
(red) after two hours of spreading. Most wild-type cells expressing GFP-skeC2 were 
completely rounded up, whereas R995A/R997A/L1000A cells transfected with 
GFP-skeC2 were fully spread. It was noted that wild-type cells with increased 
expression of GFP-skeC2 were rounded up but cells that were weakly expressing 
GFP-skeC2 had normal spreading morphology (indicated by arrow). 
68 
 
 
Figure 3.10 Immunofluorescence images reveal different effects of skeC2 
transfection on wild-type and mutant cells. Wild-type, R995A, R995A/R997A/ 
L1000A, H722A and K716A mutant cells were transiently transfected with 
GFP-skeC2 or GFP alone, plated on fibrinogen for two hours, fixed, and GFP 
fluorescence was visualized. Scale bar: 50 μm.  
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Figure 3.11 Confocal microscopy image of wild-type and R995A/R997A/L1000A 
cells transfected with GFP-skeC2. Wild-type and R995A/R997A/L1000A cells were 
transiently transfected with GFP-skeC2 or GFP alone and re-plated on fibrinogen for 
two hour. Cells were fixed and stained for integrins with AP3 antibody. Integrin 
distribution (red) and GFP fluorescence were visualized by confocal microscopy. A 
wild-type cell that weakly expresses GFP-skeC2 is indicated by an arrow. Scale bar: 
50 μm. 
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The above results indicate that skeC2 expression could abolish cell spreading and 
was more effective in wild-type cells than in mutant cells, at least in 
R995A/R997A/L1000A, H722A and K716A cells. We conclude from these results 
that transfected GFP-skeC2 competes with endogenous skelemin for integrin binding, 
thus disrupting the binding of integrin tails to not only endogenous skelemin, but to 
other cytoskeletal proteins that physically link αIIbβ3 to the cell cytoskeleton. 
 
3.2.9 Co-localization of talin and skelemin with integrin αIIbβ3 in wild-type and 
K716A mutant cells  
Among the other integrin-cytoskeleton linkage candidates, talin is similar to 
skelemin in that it also has a membrane-proximal binding region in the β3 tail, and it 
also has a distinct NPLY membrane-distal binding site (56). In addition, talin plays 
critical roles in linking integrin to the actin cytoskeleton and supporting formation of 
cell membrane protrusions during cell spreading (99, 153). Therefore, double 
labelling of integrin αIIbβ3 (red) and talin (green) or skelemin (green) was used to 
compare the distribution of talin and skelemin in wild-type and mutant cells at an 
early time point of cell spreading (40 min). Among all the mutant cell lines, K716A 
was chosen to be shown here (Figure 3.12), as it developed enormous integrin-based 
membrane protrusions of filopodia and lamellipodia during early cell spreading.  
Immunocytochemistry for β3-integrin (red) showed that cell attachment to 
fibrinogen promoted translocation of integrin from the cytosol to the cell periphery in 
wild-type cells as well as in K716A mutant cells. The K716A mutant cells had a more 
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Figure 3.12 Distribution of skelemin and talin in wild-type and K716A cells. After 
spreading on fibrinogen-coated wells for 40 minutes, (A) wild-type or K716A cells 
were fixed and stained for β3 integrin and skelemin or (B) β3 integrin and talin. 
Images were captured using a confocal fluorescence microscope. Scale bar: 50 μm. 
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profound degree of spreading level, and filopodia and lamellipodia structures were 
strikingly obvious. Co-staining for skelemin showed that skelemin colocalized with 
αIIbβ3 at the cell periphery in wild-type cells, while in K716A mutant cells it was not 
present in sheets of membrane protrusions at the cell periphery but was found to be 
localized diffusely in the main cell body, thus losing its co-localization with αIIbβ3 
(Figure 3.12A). However, both of the cell lines exhibited marked co-localization of 
αIIbβ3 and talin at the cell periphery (Figure 3.12B). Wild-type cells displayed very 
strong ring-shaped staining for both αIIbβ3 and talin at the cell periphery. This strong 
co-localization pattern is also clearly visible in the sheets of lamellipodia in K716A 
mutant cells. It seems that co-localization of talin and integrin αIIbβ3 in the regions of 
cell membrane protrusions in cells transfected with the K716A mutation could be a 
result of knocking down skelemin binding to αIIbβ3 cytoplasmic tails. 
 
3.3 Discussion 
The association of integrins with cytoskeletal proteins is crucial for the 
transmission of biochemical signals and mechanical force across these adhesion 
receptors and, thus, for integrin-mediated cell functions, such as spreading, migration 
and gene expression (154). The dynamic binding of skelemin to the cytoplasmic 
domains of integrin αIIbβ3 during the cell spreading process has been reported: 
skelemin did not bind to resting αIIbβ3 in non-adhered platelets and CHO cells; cell 
adhesion and spreading to immobilized fibrinogen promoted skelemin binding with 
αIIbβ3; and, the two proteins dissociate in later stages of cell spreading (108, 142, 146). 
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Since skelemin is a family member of myosin-associated myomesin, it was 
previously speculated to exert a contractile force by linking integrin to myosin (142). 
In the present study we tested this hypothesis and tried to elucidate the role of 
skelemin in integrin functions with the use of a series of stable CHO cell lines 
expressing mutant αIIbβ3 integrins in which key residues involved in the binding of 
skelemin to αIIbβ3 were mutated. We recognize that these mutations might also exhibit 
impaired interactions with other integrin binding proteins, and therefore we generated 
a number of mutants to reveal a general picture of the functional role of 
skelemin-integrin interactions. We found that most of the mutant cells defective in 
skelemin binding had unimpaired cell adhesion and spreading capacity at the early 
stages of cell spreading on immobilized fibrinogen. Some of the mutant cells also had 
increased membrane protrusion formation, a larger cell spreading area and elevated 
levels of activated pY416-Src. These data lead us to conclude that engagement of 
skelemin to the cytoplasmic tail of αIIbβ3 is not essential for the expansion of a cell 
protrusion during cell spreading. Instead, we propose that the binding of skelemin, 
talin and other proteins to the tail of αIIbβ3 are mutually exclusive events and 
depending on what protein is bound, a cell will either spread or contract. As discussed 
below, when skelemin is bound to the cytoplasmic tail of αIIbβ3, a contractile force is 
generated which supports cell contraction. To initiate cell spreading, a cell must 
prevent or disrupt skelemin binding to allow for the recruitment of other proteins to 
integrin clusters that facilitate cell spreading, such as talin and Src. Thus, modulating 
skelemin binding to integrin tails is one mechanism a cell can use to regulate the 
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highly organized process of cell spreading. 
Mutations of R995A and K716A in this study are shown to activate αIIbβ3. To 
address whether the activation of the mutant is caused by disruption of skelemin 
binding, we characterized the binding of PAC-1, an antibody specific for activated 
αIIbβ3 integrin, to cells overexpressing GFP-skeC2. Overexpression of this fragment 
did not alter integrin affinity state of either wild-type or active mutant cells (Figure 
3.4). Unlike talin, which is able to unclasp the membrane-proximal interface of αIIbβ3 
cytoplasmic tails and lead to integrin activation, skelemin cannot unclasp the interface 
even though skelemin also binds the membrane proximal regions of αIIbβ3 cytoplasmic 
tails. It has been demonstrated that skelemin and αIIbβ3 association occurs after 
unclasping of the αIIbβ3 interface due to integrin-ligand ligation, which unmasked 
binding residues recognized by skelemin (146). Our data here support the view that 
the association of skelemin with αIIbβ3 is a post-ligand-binding event, but not involved 
in the process of integrin-ligand affinity regulation. 
The binding of skelemin with integrin is dynamically regulated during cell 
spreading, suggesting a regulatory role for skelemin in cell spreading. Our proposed 
model for skelemin in cell spreading and anchorage is displayed in Figure 3.12. 
Focusing on cytoskeletal proteins, activation of integrins involves talin binding 
(Figure 3.12A) that results in integrin clustering and activation of FAK, resulting in 
the recruitment of skelemin and other cytoskeletal proteins to integrin clusters (Figure 
3.12B). During these early phases of cell adhesion and spreading, skelemin competes 
with other cytoskeletal proteins for binding to the β3 tail and prevents the activation of 
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Figure 3.13 Proposed model of skelemin interaction with αIIbβ3 tails. (A) 
Activation. Integrin activation involves the binding of talin (T) to the membrane 
proximal and NPLY regions of β3 that results in unclasping of the integrin tails, 
leading to αIIbβ3 binding to fibrinogen (Fg). Src is also directly bound to the 
C-terminus of the β3 tail. (B) Early stages of cell anchorage and spreading. Following 
integrin activation, integrin clustering is initiated together with the activation of FAK 
(F). This results in the recruitment of additional integrins, skelemin (Sk), and other 
cytosolic and cytoskeletal proteins to the integrin cluster, and the formation of a focal 
adhesion. (i) Skelemin binds to the membrane-proximal regions of αIIb and β3 tails and 
to the C terminus of β3 tails, which displaces Src from the C-terminus of β3, but still 
allows Src to bind to β3 via activated FAK bound to the NPLY region. (ii) In the 
presence of skelemin, talin can still bind to the β3 NPLY region but not to its β3 
membrane-proximal binding domain. (iii) The binding of other actin-binding proteins 
(ABP) to integrin tails allows for maximal Src activation while providing a linkage to 
the actin cytoskeleton. Skelemin can also provide transient linkages to the actin 
cytoskeleton (i and ii). A combination of these binding scenarios would be present 
within a focal adhesion. (C) Late stages of cell anchorage and spreading. As cell 
adhesion and spreading progresses the majority of the soluble skelemin is replaced by 
other actin-binding proteins, allowing for increased Src activation. The remaining 
skelemin makes firm contacts with the actin cytoskeleton, bringing cell spreading and 
adhesion to completion.  
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Src from occurring at the C-terminus of the β3 tail. In doing so, skelemin would 
counteract the activity of other proteins involved in cell adhesion, spreading and 
signalling, thereby providing the cell with mechanism to fine-tune its cell shape. 
During later stages of cell spreading, soluble skelemin either converts into insoluble 
skelemin, or dissociates from integrins (146), being replaced by talin or other 
actin-binding proteins, and firm adhesion occurs (Figure 3.12C).  
Previous studies reported that microinjection or over-expression of skeC2 
fragments into cultured cells abolished cell spreading (108, 142). It was assumed that 
skelemin was essential for cell spreading based on the interpretation that skeC2 
competes with the binding of endogenous skelemin to integrins but, lacks a 
cytoskeletal binding site, thus resulting in breakage of the integrin-cytoskeleton 
linkage. However, we found that mutant cells defective in skelemin binding had 
unimpaired adhesion and spreading capacity on integrin ligands, suggesting that 
skelemin binding to integrin was not essential for cell spreading. These apparently 
contradictory results can be resolved if one reinterprets the earlier study with the new 
data generated herein. We propose that the binding of skeC2 with integrin tails results 
in a loss of the control mechanisms governing the dynamics of cell adhesion and 
spreading by blocking the binding of endogenous skelemin and other cytoplasmic 
proteins to integrin tails that are important in regulating the formation of cellular 
protrusions and cell spreading. We found that the use of cells expressing receptors 
containing site-specific point mutations impeded the binding of endogenous skelemin 
(but not other cellular proteins) with the integrin tails. 
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The stoichiometry of skelemin and integrin needs to be considered when using 
GFP-skeC2 since we found that GFP-skeC2 inhibited the αIIbβ3-mediated cell 
spreading only when the proportion of GFP-skeC2 to αIIbβ3 was high (Figures 3.9 and 
3.11). The interaction between integrin and skelemin is robust. A previous NMR study 
showed that the association between skelemin C2 and integrin β3 tail is increased by 
increasing the ratio of skelemin C2 to β3 (11). If the ratio of skelemin C2 to integrin is 
much higher in plasmid-transfected CHO cells than in wild type cells, such as 
platelets, one may over-estimate or incorrectly define the role of skelemin in integrin 
biology. One problem with over-expressing skelemin C2 is that it would saturate the 
skelemin binding sites on integrins and not only block endogenous skelemin binding 
but also the association of other integrin binding partners that compete for the 
skelemin binding site. This is likely why we were able to obtain some novel insights 
into skelemin function from experiments utilizing our wild-type and mutant integrin 
cell lines, but not from skelemin C2 over-expression experiments. 
The cytoplasmic tails of αIIbβ3 are key structures for outside-in signalling in that 
they recruit a substantial number of cell signalling and cytoskeletal proteins (71). 
Notable amongst these are Src and talin, which are obligatory for cell spreading (153, 
155). Data in the current study show that the levels of pY416-Src in H722A and 
K716A cells were increased (Figure 3.7 and 3.8). Several mechanisms are brought 
into play following Src activation (151). One is the direct association of the 
C-terminal region of β3 tails with Src, which destroys the autoinhibitory state of Src 
upon cell adhesion, and integrin clustering stabilizes the activated Src by inducing 
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intermolecular autophosphorylation (115). We suggest that a reduction in skelemin 
bound to integrins may allow more Src to be bound and priming it for activation. An 
NMR spectroscopy study revealed that immunoglobulin C2-like repeat 4 (SkIgC4), 
interacts weakly with the C termini of β3 tails, which is also the binding site for Src 
involved in binding with integrin αIIbβ3 (96, 115). Therefore, it is possible that the 
binding of SkIgC4 with the C termini of β3 tails occupies the Src binding site and 
thereby reduces the capacity to maximally activate Src. However, it does not 
completely block Src activation as Src can still bind to and become activated at the 
membrane distal NPLY motif of β3 through activated FAK (156). Other 
integrin-associated proteins may play a role in upregulating pY416-Src, such as FAK, 
PTP SHP-2, and CSK (c-Src kinase), which has been demonstrated to participate in 
regulating Src activity (113, 152, 157). Mutants in the cytoplasmic tails may also 
affect the association of integrins with other modulators of Src activation.  
Recent structural studies identified the critical roles of K716 of β3 integrin in the 
αIIbβ3 interface and its interactions with αIIb via hydrogen bonds and electrostatic 
interactions (149, 158, 159). Our PAC-1 binding assay confirmed that K716A is an 
activated integrin mutant. Highly developed filopodia and lamellipodia were 
visualized at the early cell spreading stage in K716A mutant cells (Figure 3.9). 
Furthermore, the K716 residue appeared to be the most important for skelemin 
binding in in vitro studies (146). Given the overlapping binding areas within the β3 
membrane proximal region, we predict that binding of skelemin and talin to the β3 
membrane proximal region are mutually exclusive events. This is supported by our 
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findings that talin is strongly co-localized with αIIbβ3 in the ruffle structure of the 
K716A cell protrusions, but that skelemin still remained in the main cell bodies 
(Figure 3.9). Disrupting skelemin binding in K716A mutant cells may facilitate talin 
recruitment that promotes actin polymerization and membrane protrusion formation.  
Filopodia and lamellipodia are the two integrin and actin-based membrane 
protrusions formed at the leading edge of a moving cell or the periphery of a 
spreading cell that are prerequisite for cell motility and spreading (6). The elongation 
of these protrusions pushes the leading edge forward while the tail edge undergoes 
retraction enabling the cell to migrate (160). Dynamic cell spreading requires a 
balance of extending and contractile forces. In platelets, contractile forces also play an 
important role in blood clot retraction, where the fibrin meshwork is bound to αIIbβ3 
and pulled together by the platelet cytoskeleton. Contractile forces are provided by 
myosin II (79). Similar to myomesin, skelemin was thought to regulate the 
organization of myosin filaments and mediate the interaction of myosin with integrins 
(142). In our study, skelemin was not present in the sheets of lamellipodia, and 
reducing skelemin-integrin interactions promoted cell protrusion formation in K716A 
cell and cell spreading in other mutant cells. These results do not support a role for 
skelemin in generating an extending force but are consistent with skelemin exerting a 
contractile force. 
In summary, our results extend the current understanding of skelemin function as 
an integrin-cytoskeleton linker. We propose a model in which soluble and insoluble 
forms of skelemin might differ in their importance for particular integrin functions. 
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During the initial stages of cell spreading, soluble skelemin proteins bind to αIIbβ3 
integrin clusters at the leading edges of cells. These skelemin-integrin interactions 
function to coordinate the binding of different cytoskeletal proteins to the membrane 
proximal region of integrin tails, such as talin and Src (Figure 3.12B). However, the 
NPLY region remains exposed during skelemin binding and thus talin and Src can still 
bind to β3. During this time period, talin can therefore function as a linker of integrin 
and actin filaments, and maximal Src activation can be modulated by skelemin. This 
might afford a mechanism to dampen Src activation and consequently suppress 
integrin signalling. As cell adhesion and spreading progresses and large amounts of 
cell protrusion form, a majority of skelemin then dissociates from integrins to allow 
for other actin-binding proteins to bind to integrins, bringing cell spreading and 
adhesion to completion (Figure 3.12C). Concurrently, there is an increase in active 
Src levels and talin at the cell leading edges, due to skelemin dissociation. Some of 
the soluble skelemin can remain bound to αIIbβ3 and function as a linker between 
integrins and the myosin cytoskeleton, thereby transforming it into insoluble 
skelemin. 
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CHAPTER 4 
EFFECTS OF BIOACTIVE PEPTIDES DERIVED FROM 
CENTRAL TURN MOTIFS WITHIN CYTOPLASMIC TAILS OF 
αIIb AND αv INTEGRINS  
 
4.1 Introduction: 
The binding of integrin to extracellular ligands is not usually constitutive but 
precisely and strictly regulated by a process known as integrin activation. The 
regulation of integrin activation is important for physiological and pathological 
processes such as homeostasis, inflammation, and tumour metastasis. It is clear that 
the ligand binding capacity of integrin can be switched on through an affinity change 
mechanism, which is triggered by intracellular signals and transmitted by the 
cytoplasmic tails of integrin α and β subunits (45). The cytoplasmic tails propagate 
their conformational changes induced by intracellular signals through the 
transmembrane region, and cause allosteric and long-range conformational 
rearrangement within the extracellular domain of the receptor dimer (45, 161, 162). 
Studies with αIIbβ3 integrin found that the membrane-proximal α and β cytoplasmic 
domains forms a ‘clasp’ that maintains integrin in a default low affinity state (36, 39, 
158). Cytosolic proteins, such as talin and kindlin cooperatively bind to the 
membrane-distal region of β3 subunits and open the activation-constraining α-β clasp，
triggering integrin activation and ligand binding (163). Cytoplasmic tails of integrin 
can also regulate integrin-ligand binding by affinity-independent mechanisms, 
82 
 
including integrin clustering, integrin diffusion within the membrane, and linkage of 
integrins with the cytoskeleton (162, 164). Integrin lateral diffusion and clustering, 
commonly referred as avidity regulation, are secondary events occurring after the 
initial integrin affinity change and further increase cell adhesive function (61).  
Integrin α-tails are very short and more diverse compared with β-tails. Truncating 
almost the entire αIIb-cytoplasmic tail (G991–E1008) constitutively activates αIIbβ3 
(37). Cell-permeable peptides derived from full-length αIIb tail (K989–E1008) 
inhibited agonist-activated and αIIbβ3-mediated platelet binding to fibrinogen (4). 
These data indicate that the α-tail negatively regulates integrin functions. A major 
structural feature in α-tails is the central turn motif, which contains a conserved region 
in αIIb (RPPLEE) and αV (RPPQEE). NMR structures of αIIb cytoplasmic tails showed 
that in this motif, a turn structure formed at the double proline (P998 and P999) 
allowing the negatively charged C-terminus of an αIIb tail to fold back and interact 
with its N-terminal helix (4). Mutation of both prolines (P998A/P999A) completely 
abolished the inhibition of the full-length αIIb tail peptide on integrin activation, 
suggesting that the turn motif could be a key inhibitory region. It was supported by 
the observations that truncated αIIb tail peptides with the removal of the central and 
C-terminal regions activated αIIbβ3 (165, 166), while double mutation (P998A/P999A) 
of the αIIb tail expressed in CHO cells rendered αIIbβ3 constitutively active to bind 
PAC-1( anti-αIIbβ3 mAb specifically recognizing active form of αIIbβ3) (46, 167).  
To evaluate the contributions of different motifs to the α-tail’s inhibitory effect, 
we used cell-permeable peptides that derive from full length or different segments of 
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Figure 4.1: The sequences of αIIb and αv cytoplasmic tails and the peptides. (A) 
The sequences of αIIb and αv cytoplasmic tails. The amino acid sequences used in the 
experimental peptides are shown in red. (B) Sequences of the αIIb and αv peptides,  
RPP/AAA mutant and αIIb scrambled peptides. 
 
α-tails (168, 169) . The amino-termini of these peptides were coupled to myristic acid, 
which effectively targets peptides to the plasma membrane and also helps stabilize the 
secondary structure of flexible peptides (4, 170). We found that myristoylated 
peptides derived from full-length αV tails inhibited PMA-induced and αvβ3-mediated 
cell adhesion (168, 169). The turn motif peptide αV (993RVRPPQEEQ) was identified 
as the minimal inhibitory sequence in αV tail (169). However, the peptide αIIb (995–
1003) 995RNRPPLEED, which is homologous to αV (993RVRPPQEEQ), was 
functionally silent for inhibiting αIIbβ3 activation (169). As the removal of several 
amino acids from the two ends of full-length αIIb tail would not destroy the inhibitory 
capacity (4), we hypothesize that the turn motif in the αIIb tail is an inhibitory domain, 
but that extra amino acid(s) outside of αIIb (995–1003) are required for its full 
inhibitory capacity. 
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In the present study, myristoylated peptide KRNRPPLEED (named as αIIb peptide, 
Figure 4.1) was examined in assays of cell adhesion as well as soluble ligand binding 
in breast cancer cells lines (MDA-MB-435 and MCF-7) and αIIbβ3-expressing CHO 
cells. Including the lysine residue allows introduction of a biotin-tag to the lysine side 
chain. Cellular proteins that interact with αIIb peptide were also investigated. The 
homologous peptide from αV tails, myr-KRVRPPQEEQ (named as αV peptide, Figure 
4.1) was used in parallel to compare their potency to influent integrin-ligand binding.  
 
4.2 Results 
4.2.1 αIIb and αv peptides inhibited adhesion of αIIbβ3-expressing CHO cells to 
fibrinogen 
To determine whether our αIIb peptide is inhibitory for αIIbβ3-mediated cell 
adhesion, CHO cells stably expressing αIIbβ3 were used (Figure 4.2). Cells were 
labelled with fluorescent dye Calcein AM and treated with peptides as described in 
Materials and Methods. Significantly decreased cell adhesion was observed when 
cells were treated with 50, 100, or 150 μM αIIb peptide compared with its scrambled 
form (Figure 4.2A). At a higher concentration, 200μM αIIb peptide showed no 
difference from the scrambled peptide, possibly because the high concentration of 
myristoyl group was cytotoxic, leading to dramatic adverse effect on cell adhesion. 
Figure 4.2B showed that the αv peptide also had inhibitory effects on CHO cell 
adhesion at the tested concentrations.  
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Figure 4.2: Capacity of αv and αIIb peptides to inhibit αIIbβ3–overexpressing CHO 
cell adhesion to fibrinogen. (A) Measurement of cell adhesion when calcein 
AM-labelled CHO cells were incubated with αIIb or scrambled peptides for 20 minutes 
at 37°C. (B) Measurement of cell adhesion when αIIb, αv or scrambled peptide was 
introduced at the indicated concentrations. Treated or untreated cells were added to 
fibrinogen-coated wells. After adhesion, unattached cells were removed by washing. 
Adhesion was quantified by fluorescent intensity changes as indicated in Materials 
and Methods. Adhesion for untreated cells was assigned a value of 100%. The data 
shown are means and SEM from three different experiments.  * P<0.05 vs. 
scrambled peptide treatment; ** P<0.01 vs. scrambled peptide treatment, by two-way 
ANOVA. ** P<0.01 compared with scrambled peptide treatment by two-way 
ANOVA(Bonferroni’s multiple comparisons test). 
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4.2.2 αIIb and αv peptides inhibited MDA-MB-435 and MCF-7 cell adhesion to 
vitronectin  
We were interested in determining whether the αIIb peptide could inhibit αv 
integrin-mediated cell adhesion. Two breast cancer cell lines were used, highly 
metastatic MDA-MB-435 cells and poorly metastatic MCF-7 cells. Peptide effects on 
the adhesion of both cell types to vitronectin were examined. Vitronectin is a classic 
αv integrin ligand and it is abundantly expressed in cancer tissues, such as the small 
vessels surrounding breast cancer cells, and in high-grade glioblastomas (171, 172). 
αv integrin binding to vitronectin promotes cancer cell survival and migration, and 
contributes to tumour invasion and metastasis in breast cancer, melanoma and glioma 
(172-174).  
Immunofluorescence images showed that αv integrin binding to vitronectin results 
in the formation of stress fibers and focal adhesions in both types of breast cancer 
cells (Figure 4.3). Specifically, many bundles of stress fibers span the core of the 
MDA-MB-435 cells and distribution of F-actin in some MCF7 cells was condensed 
and localized at the cell periphery. Focal adhesions visualized by vinculin staining 
were also highly-developed and exhibited a dot-like distribution pattern. Our 
observations of the presence of these structures suggest that inhibiting αv 
integrin-vitronectin binding may potentially target their integrin-mediated migration 
in the two cancer cell lines. 
MDA-MB-435 cells express three αv integrin subfamily members including αvβ3, 
αvβ5 and αvβ6 (175), and all of them have the capacity to bind vitronectin (176). 
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Figure 4.4A revealed that both αIIb and αv peptides inhibited MDA-MB-435 adhesion 
to vitronectin in a dose-dependent manner. Interestingly the αIIb peptide had a similar 
inhibitory effect on MDA-MB-435 adhesion as did αv peptide. Both peptides could 
inhibit cell adhesion to vitronectin by 50% at a concentration of 8 μM, and totally 
inhibited cell adhesion at 100 μM. Various function-blocking antibodies were used to 
determine which of the three present αv-containing integrins support MDA-MB-435 
cell adhesion to vitronectin. Figure 4.4B showed that treatment with anti-αvβ3 or αvβ5 
antibodies, but not anti-αvβ6 antibody, could inhibit cell adhesion. Combined treatment 
with anti-αvβ3 and αvβ5 antibodies completely prevented cell adhesion. Taken together, 
these results suggest that αIIb and αv peptides blocked αvβ3 and αvβ5-mediated 
MDA-MB-435 cell adhesion to vitronectin. 
To further explore if the peptides are capable of inhibiting both αvβ3 and 
αvβ5-dependent cell adhesion, MCF7 cells that do not express αvβ3 were used in this 
assay (175). Both αIIb and αv appeared to inhibit MCF7 adhesion to vitronectin. 
Treatment of 25 μM peptide inhibited 50% of the cell adhesion, a lower potency of 
activity compared with the peptide’s effect on MDA-MB-435 cells (Figure 4.4C). 
Among the three different function-blocking antibodies, only anti-αvβ5 antibody 
partially inhibited cell adhesion, indicating MCF7 adhesion to vitronectin was 
primarily mediated by αvβ5 integrin (Figure 4.4D). The above data suggest that αIIb 
and αv peptides also inhibited αvβ5-mediated cell adhesion. 
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Figure 4.3: Immunofluorescence images showing stress fibers and focal 
adhesions in MDA-MB-435 and MCF-7 cells grown on vitronectin. Cells were 
grown on vitronectin-coated chamber slides for overnight, and then fixed, 
permeabilized and stained with rhodamine phalloidin to detect F-actin-containing 
stress fibers (red) and anti-vinculin antibody to detect focal adhesions (green). 
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Figure 4.4: Capacity of αv and αIIb peptides to inhibit MDA-MB-435 and 
MCF-7 cell adhesion to vitronectin. Calcein AM-labelled cells in suspension were 
incubated with αv, αIIb and scramble peptides at the indicated concentrations for 20 
minutes at 37°C (A, C), or 10 μg/mL of each antibody for 20 minutes at room 
temperature (B, D). Treated or untreated cells were then added into 
vitronectin-coated wells. After adhesion, unattached cells were removed by washing. 
Adhesion was quantified by measuring fluorescence intensity change as indicated in 
Materials and Methods. Adhesion for untreated wells was assigned a value of 100%. 
The data shown are means and SEM from three different experiments. Statistical 
analysis was performed with two-way ANOVA and Bonferroni’s multiple 
comparisons test in A and C. Statistical analysis with one-way ANOVA and Tukey’s 
multiple comparisons test in B and D. 
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4.2.3 αIIb and αv peptide inhibited the ability of αIIbβ3-expressing CHO cells to 
bind soluble fibrinogen 
Agonist-stimulated fibrinogen binding to αIIbβ3 on circulating platelets following 
vascular injury is critical for platelet aggregation and homeostasis. Wild-type αIIbβ3 
expressed in CHO cells remains in an inactive state as in non-activated platelets. The 
artificial activator Mn2+ was then used to reconstitute integrin activation and peptide 
effects on Mn2+-stimulated αIIbβ3 binding to soluble fibrinogen were investigated by 
confocal microscopy. Figure 4.5 showed that CHO cells stimulated with Mn2+ 
displayed a high amount of fibrinogen binding. Clustering of cells upon soluble 
fibrinogen binding to αIIbβ3 was visible. In contrast, the presence of αIIb or αv peptide 
decreased fibrinogen binding and cell aggregation. 
Next, fibrinogen binding levels on CHO cells treated with different 
concentrations of each peptide were measured by flow cytometry (Figure 4.6). Cells 
without Mn2+ and peptide treatment showed low fluorescence intensity, indicating 
little background fibrinogen binding. Adding Mn2+ promoted substantial fibrinogen 
binding, reflected by the right shift of fluorescence intensity. Both αIIb and αv peptide 
treatment decreased the percentage of cells that bound fibrinogen in a dose-dependent 
manner. No detectable difference of fluorescence intensity was observed when cells 
were treated with different concentrations of scrambled peptide (data not shown). 
These findings provided evidence that αIIb and αv peptides were able to inhibit Mn2+ 
promoted soluble fibrinogen-αIIbβ3 binding. However, to address whether findings in 
CHO cells are relevant to what actually occurs in human platelets, studies
91 
 
 
Figure 4.5: Confocal images showing αv and αIIb peptide inhibition of 
Mn2+-stimulated soluble fibrinogen binding to αIIbβ3-expressing CHO cells. 
αIIbβ3-expressing CHO cells were first treated with 100 μM peptides, and then 
stimulated with Mn2+ (0.2 mM). Alexa 488-fibrinogen was then added. After washing, 
cells were fixed and stained for β3 integrin. Cells in mounting media were plated on 
coverslips and visualized by confocal microscopy. 
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Figure 4.6: Flow cytometric analysis showing αv and αIIb peptide inhibition of 
Mn2+-stimulated fibrinogen binding to αIIbβ3-expressing CHO cells. 
αIIbβ3-expressing CHO cells were first treated with peptides at the indicated 
concentrations, and then stimulated with Mn2+ (0.2 mM). Alexa 488-fibrinogen was 
then added. After washing, binding of Alexa 488-fibrinogen was measured by flow 
cytometry. In the figure, the x-axis is fluorescence intensity and the y-axis is forward 
scattering. A rectangular gate was drawn to indicate dots that were considered to 
represent positively stained cells. The percentages of positively stained cells were 
indicated in the rectangular gates. 
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using thrombin or ADP-activated human platelets need to be carried out. 
 
4.2.4 Peptide mobility on SDS-PAGE gel  
The αIIb, αv, scrambled peptide and αvmut (Q998A) were examined on 20% 
SDS-PAGE gel (Figure 4.7). Staining the polyacrylamide gel with Coomassie blue 
showed that αIIb, αv and αvmut peptides migrated with the same apparent molecular 
weight, whereas the scrambled peptide migrated faster than the other peptides in the 
gels. Compared with proteins, the intrinsic charge and conformation were found to be 
important for electrophoretic mobilities of oligopeptides (177). Because αIIb and 
scrambled peptide had the same molecular weight and intrinsic charge based on their 
same amino acid composition, their different mobilities on SDS-PAGE gel suggested 
they may have different conformations. Myristoylated αIIb cytoplasmic tail peptide 
was reported to form a closed structure conformation highlighted by a turn formed at 
the double proline in the middle and electronic interactions between the two ends. We 
expect that the scrambled peptide formed an unstructured conformation as two proline 
residues were separated and positive charged N-terminus and negative charged 
C-terminus were also disrupted. A possible reason for the scrambled peptide’s higher 
electrophoretic mobility is that its disordered form may facilitate a more rapid traverse 
through the polyacrylamide matrix. From the gel electrophoresis result, it was 
hypothesized that a closed conformation, lost in the scrambled peptide, may be 
important for the inhibitory capacity of bioactive αIIb and αv peptides. 
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Figure 4.7 The scramble peptide migrates faster than αv and αIIb peptides in SDS 
gel electrophoresis. 1μg of each peptide was electrophoresed in 20% SDS gels, and 
the gel was stained with Coomassie blue. Molecular markers are shown left. The 
molecular weights of the peptides are aIIb 1.46 kDa, av 1.47kDa, scramble 1.46 kDa. 
 
4.2.5 The turn structure is important for the inhibitory capacity of αIIb peptide 
The RPP sequence, conserved in αIIb and αv tails, was predicted to form a β turn 
structure of the peptides. Previous studies have shown that a double proline mutant of 
full-length αIIb cytoplasmic peptide was functionally inactive as was the shorter αv 
peptide (4, 168). We found that mutant peptide with the RPP to AAA (RPP/AAA) 
substitution attenuated the inhibitory effects of αIIb on cell adhesion. As shown in 
Figure 4.8A, at a concentration of 8 μM, αIIb peptide treatment inhibited 
MDA-MB-435 cell adhesion to vitronectin by 58%, significantly greater than the 
RPP/AAA mutant which showed only 23% inhibition (P<0.01). Similarly, αIIb 
peptide-induced inhibition on cell adhesion was decreased by RPP/AAA mutant in 
MCF-7 cells from 53% to 30 % when 25 μM peptides were used, and in 
αIIbβ3-expressing CHO cells from 49% to 4% when 100 μM peptides were used 
(Figures 4.8B and 4.8C). These results showed that the RPP/AAA mutant peptide still 
retained some inhibitory capacity, but with a less potent effect than the αIIb peptide. 
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Figure 4.8: Decreased inhibitory capacity of the RPP/AAA mutant peptide. 
Calcein AM-labelled (A) MDA-MB-435, (B) MCF-7, (C) αIIbβ3-expressing CHO 
cells were treated with αIIb and RPP/AAA mutant peptides at the indicated 
concentrations, and then added into ligand protein-coated wells. After adhesion, 
unattached cells were removed by washing. Adhesion was quantified by measuring 
fluorescence intensity as indicated in Materials and Methods. Adhesion for untreated 
wells was assigned a value of 100%. The data shown are means and SEM from three 
different experiments. ** P<0.01 compared with αIIb peptide treatment (two 
way-ANOVA, Bonferroni’s multiple comparisons test). 
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4.2.6 Identification of intracellular binding partner 
To search for intracellular binding partners associated with the bioactive peptides, 
we performed immunoprecipitation of total cell lysate from αIIbβ3-expressing CHO 
cells with the use of biotin tagged αIIb peptide, bio-KRNRPPLEED. Biotin-tagged 
scrambled peptide was used as a negative control. Biotin-tagged peptides were first 
immobilized onto streptavidin-dynabeads and then incubated with CHO cell lysate. 
Proteins pulled down via interaction with biotin-tagged peptides were separated on 
SDS-PAGE gels and visualized by silver staining (Figure 4.9). To search for proteins 
that specifically interacted with the bio-αIIb peptide, protein bands that were present in 
higher amount in the bio-αIIb immunocomplex lane than in the bio-scrambled peptide 
lane were of interest. The 55 kD bands on the SDS-PAGE gel appeared unique in the 
bio-αIIb immunocomplex (Figure 4.9A). The bands were cut out and identified with 
mass spectrometry. The putatively identified proteins via MASCOT search are listed 
in Figure 4.9B. The results indicated that β-tubulin was enriched in the sample pulled 
down by bio-αIIb peptide. Tubulin-β5 chain and tubulin-4B chain showed higher 
protein score (protein score is -10×Log(P), where P is the probability that the 
observed match is a random event). Furthermore, the apparent molecular weight of 
the bands is 55 kD, which is consistent with the actual molecular weight of tubulin. 
The overall sequence coverage of tubulin-β5 chain and tubulin-4B chain is presented 
in Figure 4.9C. 8 peptides matching tubulin-β5 were identified with a protein 
sequence coverage of 19% (protein sequence coverage is calculated by dividing the 
number of amino acids observed by the protein amino acid length).  
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Figure 4.9: Potential identification of β-tubulin as an αIIb peptide-associated 
protein with a bio-peptide pull-down assay and mass spectrometry. (A) Peptide 
pull-down assays using bio-αIIb or bio-scrambled peptide. Bio-αIIb or bio-scrambled 
peptide was incubated with streptavidin-coated dynabeads. After washing away 
unbound peptides, the beads were then incubated with αIIbβ3-expressing CHO cell 
lysate overnight. Proteins interacting with bio-peptides were separated by SDS-PAGE 
and visualized by silver staining. The bands inside the black rectangle were cut out, 
digested with trypsin and analyzed by mass spectrometry. (B) MASCOT search 
results that indicated that β-tubulin was enriched in the sample pulled down by 
bio-αIIb peptide. Proteins listed in the column have protein scores higher than the 
threshold, which can be considered as identified (p<0.05). (C) Sequence of tubulin 
beta-5 and beta-4B chain. Recovered peptides matching the sequences of tubulin 
beta-5 (top sequence) and tubulin beta-4B chain (bottom sequence) are depicted in 
dark, whereas regions not identified by recovered peptides are shown in gray.  
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4.2.7 αv and αIIb peptides did not change the levels of p-ERK and pY397-FAK in 
MDA-MB-435 cells 
As our mutations of integrin cytoplasmic tails did not affect downstream 
signalling through FAK in CHO cells (Figure 3.7A), we then examined the role of the 
central turn motif of α-tails by studying the effects of peptides on integrin outside-in 
signalling through FAK and ERK in MDA-MB-435 breast cancer cells. 
Serum-starved cells were trypsinized and suspended in Tyrodes buffer. Cells in 
suspension were treated with or without peptides for 20 minutes and then plated on 
vitronectin. After one hour of adhesion, cells were solubilised and the levels of p-ERK 
and pY397-FAK were studied by Western blot. Figure 4.10 shows that cells contained 
constitutively activated ERK and FAK by measuring the levels of p-ERK and 
pY397-FAK in non-adherent suspension cells (the first lanes of the blots). Cell 
adhesion on vitronectin increased p-ERK levels only slightly compared with cells in 
suspension. Treatment with scr, αIIb or αv peptide did not cause any observable 
changes of p-ERK levels in the adherent cells (Figure 4.10A). Similar results were 
obtained for pY397-FAK. As shown in Figure 4.10B, pY397-FAK levels showed little 
difference when comparing adherent to non-adherent cells, and pY397-FAK remained 
at the same level in adherent cells treated with αIIb, αv or scrambled peptide. 
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Figure 4.10 αv and αIIb peptides did not change the levels of p-ERK and 
pY397-FAK in MDA-MB-435 cells. Serum-starved MDA-MB-435 cells were 
exposed to αIIb , αv and scramble peptide (100 μM each) for 20 minutes, and allowed 
to adhere on vitronectin for 2 hours. Total cell extracts were subjected to SDS-PAGE. 
Blots were probed using antibodies against pERK (P42/P44), ERK, Y397-FAK, FAK 
and β-actin.  
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4.2.8 Post-treatment with αIIb peptide did not reverse ligand-integrin engagement 
Our data showed that αIIb and αv peptides were potent integrin antagonists when 
they were pre-treated. Thus, a new question is raised whether the peptides still possess 
inhibitory capacity after the integrin is activated and ligand engagement has occurred. 
The functional consequences of peptide treatment before and after integrin activation 
were compared using platelet aggregation and cell adhesion experiments. Platelet 
aggregation assays were carried out in an aggregometer, which measures light 
transmission changes of sample solution caused by platelet aggregation. As shown in 
Figure 4.11A, adding agonists ADP/EPI induced platelet aggregation which lead to 
less light absorption and increased transmission as recorded in the aggregometer. 
Pre-incubation with 50 μM αIIb full-length CT (cytoplasmic tail) peptide before the 
addition of agonists effectively blocked platelet aggregation, indicated as the 
decreased light transmission (Figure 4.11A). However, post-treatment with αIIb CT 
peptide had no inhibitory effect on platelet aggregation (Figure 4.11B). 
We also found that the central turn peptides, αIIb and αv, could not detach 
αIIbβ3-expressing CHO cells adhered on fibrinogen (Figure 4.11C). Cells were first 
allowed to adhere to integrin ligand for one hour, and then treated with buffer or 100 
μM αIIb, αv or scramble peptide. After one more hour of adhesion, unattached cells 
were removed by washing. Cell adhesions in the presence of buffer were displayed as 
100%. No statistically significant differences were observed between the buffer and 
peptide-treated groups ((p<0.05), suggesting that neither αIIb nor αv peptide was able 
to detach αIIbβ3-expressing CHO cells from fibrinogen. Similar results were obtained 
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for adherent MDA-MB-435 and MCF-7 cells (Figure 11 D and E). 
 
 
Figure 4.10 Treatment of the inhibitory αIIb or αv peptides did not reverse 
ligand-integrin engagement. Effect of pre-treatment (A) and post-treatment (B) of 
αIIb CT peptide on platelet aggregation stimulated by ADP/EPI. (A) PRP was 
stimulated with ADP/EPI to induce platelet aggregation (indicated as ADP/EPI). 
50μM αIIb CT peptide-treated PRP were stimulated with ADP/EPI to generate an 
inhibition curve (indicated as αIIb CT). PP/AA mutant peptide was used as a control. 
(B) PRP was treated with 50μM αIIb CT peptide or control peptide five minutes after 
the agonists were added. No inhibition of platelet aggregation was observed. (C, D 
and E) Neither αIIb nor αv peptide was able to detach αIIbβ3-expressing CHO cell 
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adhesion on fibrinogen (C), and MDA-MB-435 (D) and MCF-7 (E) cell adhesion on 
vitronectin. Cells were harvested, labelled by Calcein AM, and allowed to adhesion 
on integrin ligand in Tyrodes buffer for one hour. 100μM αIIb, αv or scramble peptides 
were then added. After one more hour adhesion, unattached cells were removed by 
washing. Adhesion was quantified by measuring fluorescence intensity before and 
after wash as indicated in Materials and Methods. The buffer bars represent untreated 
groups, which were assigned a value of 100%. The data shown are means and SEM 
from three different experiments. Student’s t-test was performed and no statistically 
significant difference was found between the buffer and peptide-treated groups 
(p<0.05).  
 
4.3 Discussion 
The full-length cytoplasmic tail peptides from αIIb (989-1008) and αV (987–1006) 
suppressed the ligand binding function of αIIbβ3 and αVβ3 integrins, respectively (169). 
We previously found that peptide RVRPPQEEQ (993-1001), corresponding to the 
central motif of αV tail, inhibited αVβ3 and αIIbβ3 ligand binding, and it appeared to be 
the shortest sequence among truncated cytoplasmic tail peptides that still retained the 
inhibitory capacity. However, its homologous peptide RNRPPLEED (995-1003) 
derived from αIIb tails was functionally silent for inhibiting αIIbβ3-mediated fibrinogen 
binding to platelets (169). In the present study, αIIb peptide KRNRPPLEED (994-1003) 
that include the adjacent lysine residue was examined. We found that it blocked 
αIIbβ3-expressing CHO cells binding to immobilized or soluble fibrinogen (Figures 4.2, 
4.5 and 4.6). This work suggests the αIIb central turn motif is the inhibitory domain of 
the αIIb cytoplasmic tail and that the residue lysine (K994) is required for full 
inhibitory capacity. 
More importantly, we found that the homologous peptides αIIb (994-1003) and αV 
(992-1001) suppressed both αIIbβ3 and αVβ3 functions, which may lead to a new 
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therapeutic strategy for an anti-cancer and anti-platelet dual-role drug. Our work 
showed that peptides αIIb (994-1003) and αV (992-1001) were equally effective at 
inhibiting αIIbβ3 and αVβ3 mediated-cell adhesion to the immobilized and soluble 
ligands (Figures 4.2 and 4.4), although peptides derived from the full-length αIIb and 
αV tails can only block their parent integrin’s functions. A previous study showed that 
αIIb (989-1008) tail peptide only blocked αIIbβ3 activation, and αV (987–1006) tail 
peptide only blocked αVβ3 activation (169). The functional specificity of the 
full-length tails may attribute to their membrane proximal regions. Cytoplasmic tails 
of αIIb and β3 subunits interact to form a complex through their membrane-proximal 
regions, which maintains integrin αIIb and β3 in an inactive state (22, 23). A possible 
mechanism for the inhibitory effect of the full-length tail peptides is due to their 
competition with the native tails of their parent integrins in binding to β tails (4). Our 
recent work using surface plasmon resonance (SPR) spectroscopy found that the αV 
and β3 tails also interacted with each other (169). However, the αV turn motif peptide 
(993–1001) had low affinity for β3 tails and was ineffective at perturbing of αV-β3 tail 
interaction (169). Moreover, the highly conserved KXGFFKR motif in the membrane 
proximal region acts as a recognition site for multiple intracellular proteins. Studies 
using protein chips have identified 68 direct binding proteins to this conserved motif 
derived from different α integrin isoforms (47). However, most of these binding 
proteins are specific for different integrin family members (47), suggesting that the 
protein binding sites in membrane proximal region are different among α integrin 
isoforms. 
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The conserved amino acid composition and similar activity of αIIb and αV turn 
peptides indicate that the same functional mechanism occurs with both peptides. The 
cytoplasmic tail of the integrin αIIb-subunit has often served as a typical prototype for 
structure-function analyses (45). Here we used the wild-type, mutant and scrambled 
αIIb turn motif peptides to investigate the possible mechanism shared by the αIIb and αV 
turn motifs. 
RPP residues are important for maintaining the backbone structure of the turn. 
The NMR structure of the αIIb tail (PDB# 1DPK) showed that the turn motif allowed 
the acidic C-terminus to fold back and interact with the positively charged N-terminal, 
resulting in a “closed” conformation. However, mutation of PP (αIIb 998,999) to AA 
(PDB# 1DPQ) disrupted the turn and opened the closed conformation (4). This double 
proline mutant peptide was inactive in αIIb inhibition (4). Moreover, D-isomeric 
replacement of the αV (993-1001) at RPPQ abolished its capacity to block integrin 
activation (169). The L- to D-amino acid conversion in the αV tail may reverse the 
direction of the turn fold and the spatial orientation of the side chains. Similarly, we 
found that, compared to its original αIIb peptide (994-1003), the mutant peptide 
RPP/AAA had significantly decreased capacity for inhibiting the adhesion of 
MDA-MB-435, MCF-7 and αIIbβ3-expressing CHO cells (Figure 4.7). The αIIb peptide 
(994-1003) KRNRPPLEED retains the elements that facilitate formation of a turn 
structure: positive charged lysine and arginine residues at the N-terminus, negative 
charged glutamic acid and aspartic acid residues at the C-terminus, and double proline 
residues in the middle. In addition, K994 is possibly important for the activity of the 
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αIIb peptide because the turn structure is stabilized by K994 binding with the 
negatively charged C-terminus of the peptide. 
The NMR structure of αIIb (989–1008) and molecular models of αV (987–1018) 
suggest that the central turn motif is highly exposed and accessible to intracellular 
binding partners (168, 169). Thus, it is possible that the inhibitory activity of the turn 
peptides is due to their competition with the native turn in binding to these partners. In 
the present study, we used bio-peptide pull-down assay followed by MS/MS peptide 
sequencing to identify β-tubulin as a potential binding partner with the bio-αIIb peptide. 
Although a large number of proteins were pulled down, the protein band identified to 
be β-tubulins were enriched in bio-αIIb pull-down samples, indicating its higher 
binding affinity for αIIb peptide than scrambled peptide. β-tubulin has been previously 
shown to have high binding affinity for integrin KVGFFKR regulatory motif, the 
N-terminus of αIIb cytoplasmic tails (47). The current study potentially identified the 
binding of β-tubulin to the central turn motif KRNRPPLEED, where the first two 
amino acids (KR) overlap with KVGFFKR. Two β-tubulin-binding motifs within αIIb 
tails suggest a potential role of β-tubulin in integrin function through binding with αIIb 
tails. β-tubulin is a microtubule component. Microtubules function in intracellular 
organelle transport, mechanical support of cells and cell mitosis. Interestingly, 
microtubules have also been shown to affect integrin β2 avidity regulation (178), cell 
adhesion (179, 180) and cell spreading (64). The data presented here were consistent 
with the previous report that pharmacological disruption of microtubules inhibited 
early adhesive interactions between circulating tumour cells and host organ 
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microvasculature in vivo (179). Our findings should improve our understanding of the 
importance of microtubule-integrin linkage in integrin activation regulation and 
integrin-mediated adhesion. 
Interestingly, we also found that αIIb and αV peptides inhibited Mn2+-stimulated 
soluble fibrinogen binding to αIIbβ3-expressing CHO cells. First, confocal images 
showed that there was less labelled fibrinogen binding in cells treated with αIIb or αV 
peptide, and cell aggregation mediated by multivalent fibrinogen linking adjacent 
cells (Figure 4.5). Second, flow cytometry confirmed that αIIb inhibits soluble 
fibrinogen binding in a dose dependent manner using scrambled peptide as a control 
(Figure 4.6). Mn2+ replaces an inhibitory Ca2+ at the adjacent metal ion-binding site in 
integrin ectodomain and induces an extended and high-affinity integrin conformation 
(181, 182). Recent studies using living cells demonstrated that the conformational 
changes induced in the ectodomain by Mn2+ can be transmitted toward the 
transmembrane and cytoplasmic domains where integrin oligomers or clusters are 
formed, even in the absence of extracellular ligands (183-185). Integrin clustering 
increases the local density of integrins and recruits adaptors or cytoskeletal proteins to 
form adhesions which link cytoskeleton to extracellular matrix (3). Given that 
myristoylation allows delivery of the experimental peptides into cells and that 
nonmyristoylated peptides causes little inhibition (4, 169), our work indicates that the 
inhibitory effect of the αIIb peptide likely occurs by disturbing Mn2+-induced 
intracellular integrin clustering. Previous work found that integrin clustering did not 
spontaneously occur when integrin affinity increased, but required a driving force 
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from integrin binding partner, such as talin (185). Our data suggest that αIIb peptide 
may inhibit the interactions between αIIb tail and its binding proteins. However, 
whether β-tubulin is actually an integrin binding protein and target of αIIb turn peptide 
remains further investigation. 
Our observations showed that treatment of the agonist-stimulated platelets and 
adhered cells with the αIIb and αV peptides did not reverse ligand-integrin engagement. 
The initiating step in integrin activation is a conformational change in the integrin 
cytoplasmic tails and the transmembrane domains. The conformational changes then 
propagate from the transmembrane domains to the ligand binding headpiece, which 
increases integrin affinity for ligand. The data here indicates that the CT peptides can 
block the initiating event. However, once it has occurred it cannot be reversed as the 
numerous interactions that occur following ligand binding to stabilize the 
ligand-bound state. 
In summary, the current work suggests that the central turn motif in αIIb and αV 
tails is not only a structural support, but also an important protein anchoring site. 
Some cytosolic proteins, such as β-tubulin, may recognize and bind to the central turn, 
participating in control of integrin activation. These binding proteins function as 
activators which change α tail’s conformation (for example, opening the “closed” 
conformation), or promote integrin clustering. αIIb and αv turn peptide may inhibit 
integrin activation as a result of sequestration of the cytosolic factors. 
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CHAPTER 5 
DISCUSSION AND CONCULSIONS 
 
Bidirectional signalling across integrin receptors includes both ‘inside-out’ and 
‘outside-in’ signalling pathways. Intracellular signals trigger direct interactions of β 
cytoplasmic tails with talin and kindlin, leading to tail separation and conformational 
changes in the extracellular domain of integrin (integrin activation or inside-out 
signalling). Following ligand binding, integrins transduce signals into cells (outside-in 
signalling) by recruiting proteins to their cytoplasmic tails, which results in actin 
reorganization and modulation of signalling pathways. The cytoplasmic tails of 
integrins are short, but they serve as receivers and transmitters of the bidirectional 
signalling and are involved in assembly and disassembly of many binding partners. 
Despite years of extensive studies on specific amino acids, motifs within integrin 
cytoplasmic tails and their binding partners involved in integrin bidirectional 
signalling, a number of key questions still remain (186). What is the role of the distal 
region of α and β cytoplasmic tails in integrin activation? What are the precise 
molecular linkages between integrin cytoplasmic tails and the cytoskeleton? How do 
these interactions regulate cell adhesion, spreading and migration? Two main 
experimental approaches have been used to address these questions, specifically the 
expression of αIIbβ3 in heterologous cells, and the introduction of membrane 
permeable peptides derived from the segments of cytoplasmic tails. 
We began with an investigation of the role of skelemin-integrin binding in 
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integrin activation and cell spreading using protein mutagenesis (Chapter 3). 
Wild-type or mutant αIIbβ3 receptors defective in skelemin binding were stably 
expressed in CHO cells and their inside-out and outside-in signalling were examined.  
A previous NMR spectrometry study showed that skelemin can bind with both 
αIIb and β3 tails and had a weak capacity to separate the complex of αIIbβ3 cytoplasmic 
tails, which raises a question whether skelemin can activate integrins by unclasping 
the interface of αIIb and β3 tails. The current work showed that overexpression of the 
integrin-binding domain of skelemin (skeC2) neither activated wild-type αIIbβ3, nor 
changed the affinity state of mutant integrins in a PAC-1 binding assay. It suggests 
that skelemin cannot unclasp the membrane-proximal interface of αIIbβ3 cytoplasmic 
tails in CHO cells, even though skelemin binds both of the subunits, as does the head 
domain of talin. This result is consistent with previous immunoprecipitation results 
showing that associations of skelemin and integrin αIIbβ3 only occur following 
integrin ligation in platelets and CHO cells. It fortifies the conclusion that skelemin is 
not an upstream activator of inside-out signalling, but is more likely to be a 
downstream effector following integrin activation or inside-out signalling. 
Integrin outside-in signalling can be evaluated by cell spreading. A previous view 
regarded skelemin as an essential protein linking integrins to the cytoskeleton was 
based on the observation that microinjection or overexpression of skeC2 fragments 
into cultured cells abolished cell spreading. The skeC2 fragments were thought to do 
so by competing with endogenous skelemin binding to integrins and breaking the 
integrin-cytoskeleton linkage. Similar results were obtained here with the use of CHO 
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cells and Hek293 cells, which showed inhibited αIIbβ3-mediated cell spreading on 
fibrinogen after co-transfection with skeC2 and αIIbβ3 integrin. However, that view is 
challenged by the observation that mutant αIIbβ3-transfected cells have unchanged or 
even increased cell adhesion and spreading capacity at the early stages of cell 
spreading on immobilized fibrinogen. These cells formed membrane protrusions, 
focal adhesions and stress fibers, suggesting unimpaired integrin outside-in signalling 
leading to focal adhesion assembly and actin polymerization. These data lead us to 
conclude that engagement of skelemin to the cytoplasmic tail of αIIbβ3 is not essential 
for cell spreading.  
Some of the integrin mutant cells, namely H722A and K716A had a larger cell 
spreading area. This is in agreement with their elevated levels of pY416-Src which are 
required for integrin-mediated cell spreading. The immunofluorescence study further 
investigated K716A mutation-expressing cells, as the K716 residue appeared to be the 
most important for skelemin binding in in vitro studies. It showed that wild-type 
integrins were colocalized with both skelemin and talin in the cell periphery at the 
early stage of cell spreading, whereas K716A cells showed strong colocalization of 
talin with mutated αIIbβ3 in the cell protrusions even with a loss in skelemin binding. 
These results suggest that binding of skelemin and talin to the membrane proximal 
region of β3 tails may be mutually exclusive, and that disrupting skelemin binding 
could facilitate talin recruitment that promotes actin polymerization and formation of 
membrane protrusions.  
We hypothesize that the skelemin-integrin interactions function to coordinate the 
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binding of different cytoskeletal proteins to the membrane proximal region of integrin 
tails, such as talin. As a member of the family of myosin-associated proteins, 
skelemin was thought to exert a contractile force by linking integrin to myosin. The 
enhanced cell spreading in some mutant cells support this view. Thus, modulating 
skelemin binding to integrin tails is one mechanism a cell can use to fine tune the 
highly organized process of cell spreading. 
Meanwhile, this work also shows that the stoichiometry of skelemin and integrin 
is important for integrin-mediated function. We found that GFP-skeC2 inhibited the 
αIIbβ3-mediated cell spreading only when the ratio of GFP-skeC2 to αIIbβ3 was high. 
However, if the ratio of skeC2 to integrin is much higher in plasmid-transfected CHO 
cells than it is in wild type cells, such as platelets, this conclusion about skelemin’s 
function could be over-evaluated or even wrong, as the over-expressed skeC2 may 
saturate the skelemin binding sites of integrin and affect the association of integrin 
with other integrin binding partners that compete with skelemin. Therefore, we think 
that studies utilizing the transfection of wild-type and mutant integrin may offer an 
alternative, and perhaps better, way to evaluate the function of skelemin than simple 
overexpression of skelemin. 
Platelets are anucleate and therefore not amenable to direct genetic manipulations. 
CHO cell lines expressing wild-type and mutant αIIbβ3 have been successfully used to 
study the role of individual amino acids and specific interactions in integrin 
bidirectional signalling. Since the experiments reported here are done with CHO cells, 
the question arises whether the conclusions reached will apply to other cell types and 
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platelets. Transfection of primary megakaryocytes, the precursor of platelets, and 
generation of mice bearing mutant αIIbβ3 integrin may be considered in the future for a 
better understanding of the significance of skelemin in αIIbβ3 biology. 
Chapter 4 examines how the central motif of the αIIb tail regulates integrin 
activation and integrin-mediated cell adhesion. Previously, we located the minimal αV 
cytoplasmic tail sequence that suppressed integrin activation at the central turn region. 
The central motifs of the integrin αIIb and αV cytoplasmic tails are highly conserved. 
The present study showed that a cell-permeable peptide corresponding to the central 
motif of the αIIb tail, myr-KRNRPPLEED (αIIb peptide) inhibited αIIbβ3-mediated cell 
adhesion to fibrinogen. It also inhibited αVβ3 and αVβ5-mediated breast cancer cell 
(MDA-MB-435 and MCF7) adhesion to vitronectin. The homologous peptide derived 
from αV tails, myr-KRVRPPQEEQ (αV peptide) inhibited these cell adhesive 
functions with a similar capacity, suggesting that the two inhibitory peptides share a 
common functional mode. Structural studies show that the RPP residues are important 
for maintaining the turn structure of the αIIb tail peptide (4). In this project, 
replacement of RPP with AAA significantly attenuated the inhibitory activity of the 
αIIb peptide, suggesting that the turn structure formed by PP is important for its 
inhibitory capacity. The turn structure could be an anchoring point for some cytosolic 
factors to regulate integrin activation. 
In addition, αIIb peptide blocks soluble fibrinogen binding of αIIbβ3 integrins if 
they are activated from outside the cell by Mn2+. This result suggests that the peptide 
can interfere with the allosteric conformational changes in integrin cytoplasmic 
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domain induced by Mn2+. One possible mechanism is that the αIIb peptide may disturb 
Mn2+-induced integrin clustering in the presence of fibrinogen.  
The peptide pull-down assay identified β-tubulin as a potential novel binding 
partner with the central turn motif KRNRPPLEED within αIIb tails. However, this 
experiment was done only once and needs to be reproduced. In addition, the 
interaction between β-tubulin and αIIb peptide needs to be confirmed with other 
biochemical studies, such as SPR or co-immunoprecipitation. Moreover, whether any 
potential peptide binding with β-tubulin contributes to its inhibitory capacity was not 
addressed. The role of β-tubulin in integrin activation and/or integrin clustering 
requires extensive further studies. 
Integrin αIIbβ3 has a critical role in thrombosis and haemostasis. Active αIIbβ3 
expressed on platelets binding to fibrinogen in plasma leads to platelet aggregation, an 
important process to stop bleeding at the site of vascular injury. In contrast, abnormal 
integrin activation may result in life-threatening platelet aggregation and thromobosis 
formation. αIIbβ3 antagonists are widely used for the treatment of acute coronary 
syndromes. However, they have only shown significant promise with percutaneous 
coronary interventions. The reason for their limited use in the clinic may be due to 
their activating effects on platelet aggregation and thromobosis at low concentrations 
(135). Future antagonists will likely be designed for use as anti-platelet agents with 
the rational of maintaining αIIbβ3 in its quiescent, noncompetent state. One possible 
approach is targeting to the intracellular domain of integrin αIIbβ3 (7). Our peptides 
corresponding to the central turn motifs of cytoplasmic tails of αIIb and αV are shown 
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to inhibit αIIbβ3-mediated fibrinogen binding, and these inhibitory peptides may be a 
starting point for development of anti-thrombotic drugs. 
Thrombosis is also a common complication of patients with cancer (187). Cancer 
patients have an increase in the risk for developing thrombosis events, both in arteries 
and in veins (188, 189). Multiple and complex mechanisms contribute to 
cancer-related thrombosis, including tissue factor released by tumour cells, production 
of MP and inflammatory cytokines by tumour and/or host cells, and direct adhesion of 
tumour cells to platelets, leukocytes, and endothelial cells (187). These 
clot-promoting factors in turn contribute to tumour progression and metastasis. 
Platelets appear to be important for tumour progression as platelet-tumour cell 
interaction can protecting tumour cells from clearance by immune cells and facilitate 
their arrest in the vasculature, inducing subsequent tissue invasion (16, 190-192). 
Fibrinogen functions as a bridge between integrins αIIbβ3 on platelets and αVβ3 on 
tumour cells (191). In a mouse model, αIIbβ3 antagonists showed potential for blocking 
tumour metastasis (193). These results indicate that the combined blockade of αVβ3 
and αIIbβ3 may be effective in inhibiting tumour progression. Administration of 
abciximab, which binds both αVβ3 and αIIbβ3 with equivalent affinity, showed 
increased anti-angiogenic and anti-tumour effects compared with blocking tumour 
integrin αVβ3 alone (194). A recent study showed that anti-angiogenic drugs could 
increase invasive and metastatic properties of breast cancer cells via hypoxia-response 
program (195, 196). Therefore, combination of anti-angiogenic drugs with others 
targeting tumour metastasis may improve clinical outcome. αV integrins promote 
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tumour initiation, progression and metastasis by regulating tumour cell proliferation, 
migration and invasion, angiogenesis and ECM remodelling (129). These studies 
suggest that the homologous peptides αIIb (994-1003) and αV (992-1001) with similar 
inhibitory activity for αIIbβ3 and αV functions may lead to a new therapeutic strategy 
for an anti-cancer and anti-platelet dual-role drug. This holds clinical promise for 
cancer patients at high risk of developing thrombosis. 
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